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ABSTRACT
The Impact of Cannabis Use on Neuropsychological and Neural Biomarkers of Treatment
Response in Schizophrenia Spectrum Disorders
By
Melanie Thies
Advisor: Justin Storbeck

Cannabis use among patients with schizophrenia-spectrum disorders (SSD) is at
significantly greater levels than in healthy populations but the impact of cannabis on neural
mechanisms of clinical improvement is poorly understood. Cognitive functioning and neural
connectivity are disrupted as a result of both SSD and cannabis use, and research indicates that
neuropsychological capacity and connectivity of the striatum, a region involved in salience and
reward processing, may be integral to effective antipsychotic drug (AP) treatment response.
Despite this overlap, no previous research has investigated the effect of cannabis on the brain
functions implicated in AP treatment response. The present study aimed to explicate the
influence of recent cannabis use on previously established predictors of effective AP treatment
outcomes for patients with SSD.
The study used a cohort of medication-naïve first-episode SSD patients who used
cannabis at varying rates (i.e. both non-users (n=33) and users (n=43)). Patients were recruited
from an ongoing treatment study that consisted of a baseline functional magnetic resonance
imaging (fMRI) scan prior to beginning 12 weeks of standardized risperidone treatment, a
common second-generation atypical AP drug. Clinical interview, urine toxicology screening,
neuropsychological testing and resting-state fMRI were used to characterize the interaction
between cannabis, cognitive functioning and striatal connectivity as related to clinical
iv

Impact of Cannabis on Biomarkers of AP Treatment
improvement. The study aimed to examine the extent to which the cumulative frequency of
cannabis use prior to antipsychotic treatment influences previously established markers of
treatment response, specifically: (1) neuropsychological functioning and (2) striatal connectivity.
While the primary aims of the study were cross-sectional in nature, the longitudinal design of the
parent study allowed us to explore the extent to which the cumulative frequency of cannabis use,
prior to and over the course of AP treatment, impacted the prognostic utility of: (1) baseline
neuropsychological functioning and (2) baseline resting-state striatal connectivity in predicting
treatment response following 12 weeks of treatment.
Our results demonstrated that there was no influence of cannabis use on baseline
measures of neuropsychological functioning or striatal connectivity. There were also no
differences between patients who responded to AP medications versus non-responders in
neuropsychological functioning or striatal connectivity. However, there was evidence for a
potential interaction effect between cannabis and striatal connectivity in regard to treatment
response. Future research with a larger sample size is needed to further investigate the impact of
cannabis on the utility of striatal connectivity in predicting treatment outcomes. As legalization
of cannabis becomes increasingly widespread across the United States, it will be crucial to
understand cannabis’ effect on treatment-related neural circuitry in order to create brain
biomarkers that are generalizable to the large proportion of patients who use cannabis.
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Introduction
Schizophrenia spectrum disorders (SSD) are estimated to occur in approximately ~1% of
people and cannabis use among this patient population is disproportionately higher relative to
healthy individuals (Desai, Lawson, Barner, & Rascati, 2013; Fischer, Whitfield-Gabrieli, Roth,
Brunette, & Green, 2014; Kessler et al., 2005; Wisdom & Manuel, 2011; Wu, Shi, Birnbaum,
Hudson, & Kessler, 2006). Antipsychotic (AP) drug treatment is the mainstay for treatment of
these disorders but clinical response to these medications is variable and unpredictable (Conley
& Kelly, 2001; Leucht et al., 2013). As such, a primary goal of current research is to identify
neurocognitive and neural circuitry-based biomarkers that predict which patients will respond to
antipsychotic treatment versus those who will not.
Cognitive functioning and striatal regions (involved in salience and reward processing)
are disrupted in individuals with SSD (Jensen & Kapur, 2009; Kuepper et al., 2010), and recent
research has reported that neuropsychological performance and striatal connectivity at the
beginning of AP treatment may be critical to predicting effective clinical response (Sarpal et al.,
2015, 2016; Trampush et al., 2015). Notably, cannabis is associated with acute aberrancies in
neuropsychological functioning and striatal connectivity, but its influence on the cognitive
domains and neural circuitry previously implicated in effective AP treatment is poorly
understood (Fischer et al., 2014). Without this knowledge, the prognostic accuracy of
established biomarkers may not be generalizable to the substantial number of patients using
cannabis during AP treatment. The present study aims to explicate the effect of cannabis use on
cognitive and neural markers associated with AP treatment response. These findings will inform
efforts to create biomarkers of clinical response that generalize to the ~35% of SSD patients
estimated to use cannabis during treatment (Burns, 2012; Wisdom, Manuel, & Drake, 2011).
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Cannabis Use in Schizophrenia Spectrum Disorders
Compared to the general population, cannabis use and misuse are significantly
heightened in patients with SSD, particularly in patients experiencing their first-episode of SSD,
defined as the period during which a patient experiences initial symptoms of psychosis
(Breitborde, Srihari, & Woods, 2009). Patients with SSD have a 10-fold increased risk of
comorbid cannabis use disorders (CUD) (Fischer et al., 2014), an illness characterized as a
pattern of repeated cannabis use that results in harmful consequences that cause an individual
significant distress or functional impairment (American Psychiatric Association, 2013).
Moreover, even in the absence of CUD, patients with SSD report current cannabis use four times
more frequently than healthy samples (Azofeifa et al., 2016; Wisdom & Manuel, 2011).
The Center for Behavioral Health Statistics and Quality’s most recent survey of substance
use trends in America reports that 45.20% of Americans 12 years and older have tried cannabis
at least once in their lifetime, and 8.3% have used it within the last month (Hedden, Kennet,
Lipari, Medley, & Tice, 2015). In contrast, approximately 60% of first-episode patients report
trying cannabis at least once in their lifetime and 30-40% report current use. Data from the
National Epidemiologic Survey on Alcohol and Related Conditions (NESARC-III), a survey of
36,309 participants, indicate that the lifetime prevalence of CUD in the United States is
estimated to be 6.27% of individuals with only 2.54% meeting criteria within the last 12 months
(Hasin et al., 2016). Comparatively, a meta-analysis of the epidemiology of CUD in SSD
patients (5,572 patients from 35 studies) found that 44.4% of first-episode SSD populations will
meet DSM-V criteria for CUD in their lifetime and that 28.6% currently meet criteria for CUD
(Koskinen, Löhönen, Koponen, Isohanni, & Miettunen, 2010).
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SSD patients are also more likely to engage in heavier and more chronic patterns of
cannabis use compared to non-psychotic samples. In a study that compared 280 first episode
patients to 174 healthy controls, first episode patients were more likely to use cannabis daily
(76.9% vs. 33.3%; Odds Ratio (OR) = 6.7) and for longer than 5 years (59.2% vs. 37.5%; OR =
2.4). Additionally, compared to healthy controls, the patients were more likely to report an early
age of first cannabis use (65.3% versus 52.2%; OR = 1.7) and the use of higher-potency cannabis
(78.4% versus 37.4; OR = 8.1) (Di Forti et al., 2009).
Heightened cannabis use in SSD patients is especially concerning because of the negative
impact CUD can have on patient prognosis. Patients with concurrent CUD evidence significantly
worse outcomes than patients without a comorbid diagnosis. Specifically, cannabis use in SSD
has been linked to a greater number and severity of psychotic symptoms, increased likelihood of
psychotic relapse and hospital readmission (Buckley, Miller, Lehrer, & Castle, 2009; Schoeler et
al., 2016b), medication non-adherence and poorer global functioning (Henquet et al., 2010;
Hides, Dawe, Kavanagh, & Young, 2006; Swendsen, Ben-Zeev, & Granholm, 2011; Zammit et
al., 2008).
Despite the established elevated prevalence of cannabis use in SSD patients, research on
the impact of cannabis on treatment outcomes for this population is mixed and its potential
influence on predictors of treatment response has been largely ignored.
Predictors of Treatment Response in SSD
The large variability of clinical improvement among SSD patients has driven research to
identify factors that may contribute to favorable patient prognoses. While a range of variables
have been examined towards this goal, including genetic and demographic characteristics, this
section will focus on reviewing research on neuropsychological and neuroimaging markers of
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treatment response given evidence for the impact of cannabis on brain functioning, which will be
expanded upon in subsequent sections.
Neuropsychological Performance as a Predictor of AP Treatment Response
The characteristics associated with SSD are most commonly divided into “positive” and
“negative” domains of symptoms. Positive symptoms refer to those that are “added” to a
patient’s life, referring to intrusive delusions, hallucinations and disorganized speech/behavior.
Negative symptoms represent a loss of some capacity, such as reduced emotional expression
(blunted or flat affect), impoverished speech (alogia) and inability to initiate goal-oriented
behavior (avolition). SSD are frequently accompanied by cognitive impairments that interfere
with a patients’ ability to organize their lives and operate effectively at home and work. These
symptoms include deficits in higher-order functions such as working memory, learning,
attention, explicit memory, and executive functions (e.g. problem solving, cognitive control)
(Cirillo & Seidman, 2003; Goldman-Rakic, 1994; Simpson et al., 2010). Relative to healthy
individuals, SSD patients demonstrate reduced performance in neuropsychological tasks that
measure these domains (Bilder et al., 2006; Mesholam-Gately et al, 2009; Fatouros-Bergman et
al., 2014). Deficits in both general intellectual functioning (e.g., IQ) and specific domains (e.g.,
attention, memory, reasoning, executive functioning, and verbal abilities) have also been
consistently observed in children and adolescents who later go on to develop an SSD relative to
typically developing individuals (Sheffield, Karcher, and Barch, 2018).
Neurodevelopmental models of SSD conceptualize these premorbid cognitive symptoms
as early indication of overall aberrant neurodevelopment that ultimately leads to the development
of psychosis (Mollon & Reichenberg, 2017; Seidman & Mirsky, 2017). Indeed, in contrast to
psychotic symptoms that typically appear between ages 18 and 25, cognitive deficits emerge
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earlier in the lifespan (Cornblatt et al., 1999). Cognitive impairments have been considered a risk
factor for the development of SSD (Kahn & Keefe, 2013). A meta-analysis of 4000 SSD
patients and 700,000 control subjects demonstrated that low IQ increases the risk of SSD in a
dose-response fashion; for every point decrease in IQ, there is a 3.7% increased risk of SSD
(Khandaker, Barnett, White, & Jones, 2011). Another meta-analysis that included studies that
evaluated subjects aged 16 years and younger also found low IQ to increase schizophrenia risk,
suggesting that this risk is present even early in life (Dickson, Laurens, Cullen, & Hodgins,
2012). Genetic studies have demonstrated there may be a shared genetic effect underlying the
relationship between increased risk for schizophrenia and cognitive dysfunction (Aukes et al.,
2009; Toulopoulou et al., 2010). In turn, this leads to cognitive decline both prior to illness onset
and throughout the course of the disease, and serves as a predictor of functional outcomes (Kahn
& Keefe, 2013; Seidman & Mirsky, 2017).
Such evidence for cognitive dysfunction as part of the pathophysiology of SSD has
supported research on the important role of cognition in clinical outcomes. Research suggests
that neuropsychological performance prior to treatment may index responsivity to AP drugs such
that stronger cognitive functioning at the beginning of treatment is associated with a greater
likelihood of clinical improvement. Compelling evidence for the prognostic utility of
neuropsychological functions is provided by our research group (Trampush et al. 2015). They
previously conducted a longitudinal study of 109 first-episode patients in a randomized
controlled trial of two commonly used antipsychotics, aripiprazole or risperidone. Patients were
administered clinical rating scales and the MATRICS Consensus Cognitive Battery (MCCB)
pre-and-post 12 weeks of AP treatment. The MCCB is a repeatable battery commonly used in
SSD research that measures seven cognitive domains (Processing Speed, Working Memory,
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Reasoning and Problem Solving, Verbal Learning, Visual Learning, Attention/Vigilance and
Social Cognition) and provides an overall composite store that indexes general cognition.
Clinical symptom rating scales were used to divide the sample into patients who responded to
APs versus patients who were non-responders, based on stringent criteria of positive symptom
improvement over the trial. Results demonstrated that stronger baseline Reasoning and Problem
Solving scores predicted a greater likelihood of clinical improvement 12 weeks later.
Furthermore, when the researchers classified individuals as high, average, or low performers
based on percentile ranks of Reasoning and Problem Solving scores within the sample, they
found that only 40% of the low-performance group responded to treatment compared to 80% of
patients in the high-performing group. The association remained even when controlling for
baseline psychotic symptom severity and relevant demographic variables (Trampush et al.,
2015).
Other studies have produced similar findings. An observational study of 28 first-episode
patients observed that first-episode patients with stronger baseline scores on the MCCB
Attention/Vigilance domain were more likely to have reduced positive symptoms following 6
months of treatment. Additionally, stronger performance on the Working Memory and
Attention/Vigilance domains at baseline predicted better social and role functioning at follow-up.
Given the observational nature of the study, these results are limited by potential confounding
effects of varying medications; though the majority of patients were on second-generation
antipsychotics (Torgalsboen, Mohn & Rund, 2014).
Similarly, a study of first-episode patients treated with fluphenazine found that stronger
attention and working memory performance, as measured by the MCCB, significantly predicted
positive symptom improvement over the first year of treatment (Robinson et al., 1999). Another
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treatment study of 55 patients randomized to risperidone, olanzapine or aripiprazole evaluated
predictors of remission in the acute phase of illness for first-episode patients. Results
demonstrated that greater scores on measures of verbal memory (as measured by the Hopkins
Verbal Learning Test) and prospective memory (measured by the Cambridge Prospective
Memory Test) at baseline predicted positive symptom improvement after 8 weeks of treatment
(Zhou et al., 2013). Taken together, these studies suggest the potential for brief paper-and-pencil
measures of neurocognitive functioning to provide prognostic information about the likelihood
of treatment response. Though the specific cognitive domains have varied across studies, the
neuropsychological functions found to be predictive align with domains observed to be impaired
in SSD patients. The mixed results may be explained by diverse sample characteristics and the
cognitive batteries used, and could be addressed by additional research that uses controlled
samples and standardized measures.
Striatal Connectivity as a Predictor of Antipsychotic Treatment Response
Efforts to develop neuroimaging-based biomarkers have utilized findings from research
on the brain mechanisms that contribute to the etiology of SSD. Striatal abnormalities have long
been acknowledged to play a prominent role in psychotic symptomology. The striatum is a
neural region implicated in multiple psychiatric disorders, including substance use and SSD
(Abi-Dargham et al., 2000). It is involved in reward processing, whereby individuals appraise,
learn from and seek rewards, and salience processing, by which individuals evaluate their
environment and assign meaning to relevant stimuli. The striatum is divided into the: (1) dorsal
striatum (DS), which includes the caudate and putamen and is involved in inhibitory control,
stimulus-response learning and salience processing (Zink, Pagnoni, Martin, Dhamala, & Berns,
2003); and (2) ventral striatum (VS), which includes the nucleus accumbens and is considered
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the “reward center” for its role in pleasure seeking and reinforcement learning (Haber, 2011).
The striatum contains a substantial quantity of dopamine receptors and an aberrant striatal
dopaminergic system is proposed to underlie psychopathologies such as addiction and psychosis
(Grace, 2016; Wise, 2009).
Early theories on the involvement of dopamine in the development of psychosis stemmed
from observations that drugs that induce striatal dopamine release cause psychotic-like
symptoms while medications that block dopamine (i.e. antipsychotic medications) reduce
psychosis (Howes & Nour, 2016). The “original dopamine hypothesis” was proposed after
observation that drugs that blocked dopamine receptors improved symptoms of psychosis; it
posited that positive psychotic symptoms in SSD were the result of hyperactive dopamine
transmission throughout the brain (Seeman & Lee, 1975; Van Rossum, 1966; Creese, Burt &
Snyder, 1976; Madras, 2013). This theory drew increasing support from neuroimaging research.
Positron emission tomography (PET) studies demonstrated that positive symptoms were related
to enhanced activity in VS and associated limbic structures (Liddle et al., 1992), and that
dopamine production and release capacity were increased in SSD patients in the striatum and
midbrain (Howes et al., 2012).
The dopamine theory has since been refined after observing that not all SSD symptoms
were improved by the administration of dopamine blockers. The “revised dopamine hypothesis”
currently proposes that schizophrenia is associated with hyperactive dopamine activity in
mesolimbic areas (i.e. striatum, ventral tegmental area, amygdala and hippocampus) coupled
with hypoactive dopamine activity in prefrontal cortex (Davis et al., 1991; Brisch et al., 2014; da
Silva Alves, Figee, van Amelsvoort, Veltman, & de Haan, 2008; Pogarell et al., 2012; Walter,
Kammerer, Frasch, Spitzer, & Abler, 2009). Though the relationship between dopamine activity
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and brain activity in humans is not fully understood, striatal dopamine appears to modulate
neural connectivity. Excessive striatal dopamine release is also demonstrated to induce
spontaneous activity in the striatum, essentially creating “noise” in brain signaling, which is in
turn, linked to abnormal prefrontal activation that has been demonstrated to disrupt cognition,
reinforcement learning and salience processing (Fusar-Poli et al., 2011; Sorg et al., 2013).
Furthermore, increased dopaminergic reuptake in the striatum is related to reduced prefrontal
activation in SSD (Meyer-Lindberg et al., 2002).
This pattern aligns with fMRI studies that show a functional coupling of the striatum and
prefrontal regions and support a “disconnectivity hypothesis” of schizophrenia which suggests
that schizophrenia is characterized by dysfunctional integration of brain regions with one
another, at both a global whole-brain network level and a local connection level between select
regions (e.g. cortical to subcortical pathways) (Friston, 1998; Stephan, Baldeweg & Friston et al,
2006; Liang et al., 2006). There is evidence for decreased functional connectivity throughout the
SSD brain at rest (Liang et al., 2005), as well as reduced frontostriatal connectivity, both of
which are related to increased psychotic symptomology (Jensen & Kapur, 2009; Juckel et al.,
2006; Shukla et al., 2018; Sorg et al., 2013). Taken together, these data support an “aberrant
salience hypothesis” of schizophrenia which proposes that striatal dysfunction at both the
neurotransmitter level (i.e. dopamine release and synthesis) and at the functional connectivity
level results in impaired salience processing. It posits that excessive dopamine coupled with
attenuated connectivity between the striatum and cortical regions causes individuals to
inaccurately assign meaning to irrelevant environmental events, which may lead to the
experience of delusional thinking and hallucinatory experiences (Howes & Nour, 2016).
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Given that dysfunctional dopaminergic striatal circuitry is implicated in SSD etiology
(Liddle et al., 1992; McGowan, Lawrence, Sales, Quested, & Grasby, 2004; Nielsen et al., 2012;
Tu, Lee, Chen, Li, & Su, 2013), most SSD treatments target dopamine D2 receptors, of which a
substantial quantity reside in the DS and VS, and appear to normalize striatal aberrancies in
regard to both dopamine activity and functional connectivity with other neural regions. Atypical
antipsychotic treatment medications have been found to increase connectivity of the DS and VS
to cortical targets (dorsal frontoparietal and ventral fronto-insular, respectively). For example, a
PET study in 29 patients with SSD demonstrated that AP treatment increased resting cerebral
blood flow in the VS, which was associated with a reduction in positive symptoms (Lahti,
Weiler, Holcomb, Tamminga, & Cropsey, 2009). Moreover, treatment responders have been
found to exhibit elevated striatal dopamine synthesis and release while treatment-resistant
patients do not show such dopamine alterations in the striatum, suggesting that APs are effective
by way of stabilizing striatal dopaminergic aberrancies (Howes & Kapur, 2014). A small study
of first-episode schizophrenia patients demonstrated that 6 weeks of treatment with amisulpride,
an antipsychotic medication, normalized originally deficient ventral striatum activations during a
reward task (Nielsen et al., 2012).
The involvement of striatal activity/connectivity in clinical improvement is further
strengthened by recent evidence that striatal connectivity can predict treatment response. Our
research group previously demonstrated that a baseline striatal connectivity index (SCI), a
measure of the strength of striatum’s connectivity with other neural regions, can be used as a
biomarker to predict AP treatment response in SSD patients (Figure 1). In this study (Sarpal et al
2016), a sample of 41 patients experiencing their first episode of SSD who had no more than 2
weeks of cumulative lifetime exposure to AP medications participated in a double-blind
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randomized controlled trial of aripiprazole or risperidone. Patients received clinical rating scales
and an fMRI scan pre-and-post 12 weeks of AP treatment. Patients were grouped into
responders and non-responders based on strict criteria of psychotic symptom improvement. The
authors used resting-state fMRI to generate whole-brain functional connectivity maps for each
subject from established striatal seed regions (Di Martino et al., 2008) which allowed for
functional connections (between the striatum and other brain regions) that predicted treatment
response to be identified. Ninety-one connections were identified that were significantly
associated with treatment response and were combined into a single striatal connectivity index.
The SCI demonstrated 80% sensitivity and 75% specificity for predicting which patients would
respond to AP treatment versus those who would not; this finding was replicated in an
independent sample of chronic SSD patients (Sarpal et al., 2016). The results of the study
support the potential for individual differences in striatal functional connectivity to predict AP
response.
Specifically, AP treatment response was associated with lower baseline functional SCI to
frontal cortical regions (Sarpal et al., 2016) (Figure 2). Moreover, the study demonstrated that
symptom reduction was linked to pre-to-post increases in functional striatal connectivity
between: (1) DS and frontal regions (e.g. dorsolateral prefrontal cortex (DLPFC), anterior
cingulate cortex (ACC), and orbitofrontal cortex (OFC); and (2) VS and hippocampus, and
insula (Figure 3) (Sarpal et al., 2015). These findings suggest that normalization of frontostriatal
connections may underlie successful improvements in psychotic symptoms (Sarpal et al., 2016).
Normalization of frontostriatal connectivity by antipsychotic treatment has also been similarly
demonstrated by other research groups studying early-phase SSD patients (Anticevic et al.,
2015).
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While additional studies have found support for the potential for the connectivity of the
striatum to predict treatment response (Li et al., 2020), others have demonstrated evidence for
different brain regions to provide prognostic information about clinical outcomes, including the
ventral tegmental area, superior temporal cortex, and the hippocampus (Cao et al., 2018; Hadley
et al, 2014; Lahti et al., 2009). Though the specific brain regions may vary across studies, they
are typically neural areas that are functionally connected to the striatum, further supporting the
importance of this region in treatment outcomes. Diverging results may be a result of differing
neuroimaging methodology, small samples, and an inconsistency in prior/current medication
exposure of patients. Future research that uses larger sample sizes and controlled medication
trials will be important to validate these biomarkers and translate them into clinical use.
Impact of Cannabis on Predictors of Treatment Response
The discovery of predictors of treatment response is an exciting and promising area of
research with important clinical implications for patients. However, the prognostic accuracy of
such markers may be substantially impacted by external factors that impact cognitive functioning
and striatal circuitry, such as substance abuse, resulting in substantial reductions in their utility.
Cannabis is a primary area of concern in the development of biomarkers for SSD because of its
aforementioned significant use in this population. This section will review evidence to support
the potential for cannabis to influence the previously described predictors of treatment response,
underscoring the importance of the present project.
Impact of Cannabis on Cognitive Functioning in SSD
As previously mentioned, cannabis use in SSD patients has been linked to greater
severity of psychotic symptoms. Inductions of delta-9-tetrahydrocannabinol (THC; the primary
psychoactive ingredient in cannabis) are found to cause psychotic-like experiences in both
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healthy individuals and individuals at clinical high risk (CHR) for developing an SSD, as well as
exacerbating positive and negative symptoms in patients with an existing SSD (D’Souza et al.,
2005; Vadhan et al., 2017).
Acute consumption of THC is also associated with cognitive impairments in SSD
patients. In a double-blind, randomized, placebo-controlled trial, an administration of
intravenous THC was given to 13 stabilized SSD patients with some history of reported cannabis
use and 22 healthy controls prior to a cognitive assessment. Relative to performance after
placebo administration, both SSD and healthy individuals showed impairments in memory and
attention. The SSD group showed a significantly greater reduction in cognitive functioning after
THC relative to the control group. The results provided evidence for cannabis’ ability to
transiently worsen cognitive functioning and suggests that SSD patients are particularly
vulnerable to the neuropsychological impact of THC (D’Souza et al., 2005). A similar pattern
was seen in a sample of cannabis users at clinical high risk for developing psychosis (CHR). In a
preliminary study (N = 12) that examined the immediate psychological and neurocognitive
effects of smoked active cannabis compared to placebo cannabis in CHR and healthy individuals,
CHR patients demonstrated decreased performance on tasks of working memory and response
inhibition in response to the active cannabis, two higher-order cognitive functions typically seen
to be impaired in SSD patients (Vadhan et al., 2017).
Surprisingly, while acute cannabis use appears to have a detrimental impact on cognition,
SSD patients with a history of regular cannabis use have been found to have better overall
cognitive functioning, when tested in a non-intoxicated state. Findings from numerous studies
have suggested that patients who use cannabis tend to perform better on neuropsychological tests
relative to patients who are non-users. A meta-analysis of 10 studies that included 572 patients
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with schizophrenia was conducted to evaluate differences in neuropsychological functioning
between patients with and without a history of cannabis use and found that patients with a history
of cannabis use had superior cognitive functioning (Yucel et al., 2012). A separate meta-analysis
of 942 patients from 8 studies also found superior performance in cannabis-using patients across
cognitive domains (Rabin, Zakzanis, & George, 2011). A number of studies assessing the effects
of cannabis on neurocognition in first-episode SSD patients have also demonstrated that cannabis
users perform better than or equivalent to non-users in verbal memory, working memory,
executive functions, planning and visual memory (Leeson et al., 2012, Bugra et al, 2013; Nunez
et al., 2015)
One study of 85 first-episode patients with (N = 59) and without (N = 26) a history of
regular cannabis use were compared to 43 healthy non-using controls to examine
neuropsychological differences between groups on 16 tasks across 6 cognitive domains (General
Intellectual Ability, Processing Speed, Visual Memory, Verbal Memory, Working Memory,
Executive Functioning). Patients without a history of regular cannabis use showed more general
impairments compared to healthy controls, demonstrating weaker performance on 15 of the 16
tasks; premorbid IQ was the only task where there was no significant difference. In contrast,
patients with a history of regular cannabis use only demonstrated selective impairments on 9 of
the 16 tasks, primarily in verbal memory, processing speed, working memory and executive
functioning (Yucel et al., 2012).
A significant limitation of findings that cognition is stronger in cannabis-using patients is
the heterogeneous definitions of cannabis consumption used across studies. For example, some
studies define cannabis users as having tried cannabis at least once in their lifetime whereas other
studies define use as a certain number of times per month or week. Furthermore, there is often
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little information provided about the time since last use, or whether patients specified to have a
“history” of cannabis use are currently using or have become abstinent. Studies also frequently
lack control for variables with a potential confounding effect on cognition such as type/duration
of antipsychotic medications, and variables related to patterns of cannabis consumption (e.g.
frequency, amount, duration) (Nunez et al., 2015). Additional research that includes information
on the recency of cannabis use is critical in order to better understand the temporal impact of
cannabis use on cognition.
A study by Nunez et al. (2015) attempted to correct for shortcomings of prior studies by
dividing a sample of 74 first-episode patients into three different groups based on average
cannabis consumption in the last year (non-users, medium users, and heavy users). Participants
completed a neurocognitive battery that included tests of verbal memory, attention, processing
speed, executive functioning, working memory, vocabulary, and spatial orientation. Results
showed that patients with heavy cannabis consumption demonstrated impairments in verbal
memory relative to medium and non-users, and medium users also showed impairments relative
to non-users. Heavy users performed worse than medium users in processing speed, working
memory, and attention. Findings suggest a “dose-related” effect of cannabis consumption on
cognitive impairment and indicate that ongoing cannabis use may impede cognitive functioning.
In sum, evidence suggests that cannabis influences cognitive functioning, though the
directionality of this relationship varies depending on how cannabis use is defined (i.e., how
much and how recently cannabis has been used). While patients with a history of cannabis use
may initially have superior cognition that allowed them to begin and sustain use, those patients
with ongoing use appear to evidence detrimental impact on cognition, perhaps because of the
acute/residual worsening of cognition that THC induces. If neuropsychological performance is to
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be used as a predictor of treatment response, and ongoing cannabis use is known to impair
cognitive abilities, it is critical that research to develop neuropsychological markers of
responsivity accounts for ongoing cannabis use during treatment.
Impact of Cannabis on Striatal Circuitry
It is equally critical that efforts to develop neuroimaging biomarkers consider the
influence of cannabis because studies have demonstrated that cannabis is known to impact brain
activity and connectivity. The effects of cannabis are especially prominent in the striatum; a
relationship that is concerning given the integral role of this region in outcomes for SSD patients.
Models of drug addiction propose a dysfunctional striatal dopamine system in which there is
reduced functional connectivity between the pleasure-seeking striatum with prefrontal cortex’s
behavioral and cognitive control centers. Attenuated activation between these regions is
hypothesized to make individuals susceptible to the overuse of pleasure-inducing substances
(Tomasi & Volkow, 2013).
Cannabis is found to influence striatal circuitry in the brain through its impact on
dopamine and related circuitry. In animal studies, acute cannabis inductions cause an increase in
dopamine release and striatal neuronal firing (Oleson & Cheer, 2012; Tanda, Pontieri, & Di
Chiara, 1997). In non-psychotic human samples, early research on the immediate effects of
cannabis use is less consistent but also suggests an alteration of striatal activity. Following
inductions of THC, one study demonstrated increased striatal dopamine release (Bossong et al.,
2009) while another found no effect (Stokes, Mehta, Curran, Breen, & Grasby, 2009). These
studies were criticized for small samples (N= 9-13) and being underpowered (Bossong et al.,
2015). However, an analysis of the combined sample from these two conflicting studies (N= 20)
provided more compelling evidence that THC does acutely increase striatal dopamine in humans.
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In contrast, chronic cannabis use is linked to blunted striatal dopamine release with one
study linking reduced dopamine to subclinical psychopathology. This study (van de Giessen et
al., 2017) compared individuals with severe cannabis dependence (without any comorbidities) to
healthy controls using a PET scan with [11C])-(+)-PHNO (a dopamine D2/3 receptor agonist
tracer), and found that those with cannabis dependence demonstrated lower dopamine release in
the striatum in response to an amphetamine induction. Participants were also administered
clinical and neurocognitive assessments which revealed that lower dopamine release was
associated with subclinical levels of the types of symptoms typically seen in SSD patients.
Specifically, those with cannabis dependence evidenced greater negative symptoms and reduced
attention, working memory and probabilistic category learning (Trifilieff & Martinez, 2014; van
de Giessen et al., 2017). Furthermore, fMRI research demonstrates that chronic cannabis use, as
well as THC consumption in non-SSD subjects immediately prior to fMRI, attenuates restingstate functional connectivity (RSFC) in the striatal circuits known to be aberrant in SSD patients,
specifically between: (1) DS and prefrontal cortices (PFC); and (2) VS and limbic regions (e.g.
hippocampus) (Bhattacharyya et al., 2015; Blanco-Hinojo et al., 2017; Ramaekers et al., 2016),
though effect sizes have ranged from small to large across studies. An fMRI study of 15 healthy
occasional cannabis users examined performance on a visual salience processing task following
an induction of THC. Participants completed a visual oddball detection task in the scanner which
involved selecting a button to indicate the direction of a series of arrows presented on a screen
interspersed with random stimuli to induce salience processing to novel images and evaluate
differences in neural and behavioral responses to each. They found that THC caused reduced
frontostriatal connectivity which was related to impaired task performance by reducing response
time (Bhattacharyya et al., 2015). Findings that cannabis impacts the frontostriatal network
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suggests that cannabis may cause psychosis by further challenging an already-vulnerable striatalcortical network (Bhattacharyya et al., 2015).
Substantially fewer studies have examined cannabis use in SSD populations. Those that
have been conducted generally use structural imaging and are hampered by methodological
issues contributing to conflicting findings. Namely, they lack control for confounding variables
such as medication type/quantity and length of previous clinical trial duration (Rais et al., 2008).
However, these studies generally show an association between cannabis and neural changes.
Cross-sectional structural MRI studies demonstrate that cannabis-using SSD patients exhibit
reduced gray matter in striatal, limbic and frontal regions (Batalla et al., 2013; James et al., 2011;
Malchow et al., 2013; Martin-Santos et al., 2010). Consistent with these studies, the sole
longitudinal structural MRI study to track SSD patients over a five-year period shows that
cannabis users evidence greater grey matter volume reductions and ventricle enlargement than
non-users (Rais et al., 2008).
To date, only one study has been conducted in which SSD patients were administered
cannabis prior to an fMRI scan (Fischer et al., 2014). The sample consisted of 12 patients with
comorbid SSD and CUD compared to 12 non-SSD and non-CUD control subjects. Both groups
completed fMRI scans pre-and-post an administration of either a THC cannabis cigarette or THC
capsule. At baseline, the patients showed significantly reduced connectivity between the nucleus
accumbens and prefrontal cortical regions (anterior PFC, OFC, and ACC) relative to healthy
controls. Post-THC induction, THC significantly increased connectivity between VS and ACC,
OFC, and PFC in the patient group only. The authors suggest that cannabis use in SSD may
ameliorate existing dysfunction in the brain’s striatal reward circuitry and may partially explain
the increased prevalence of cannabis use in SSD patients. However, this study is limited by its
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small sample size (N= 12), a lack of control for previous AP treatment, and absence of a
comparison group of SSD patients without CUD; future studies are necessary to confirm the
findings (Fischer et al., 2014).
Taken together, although the pattern in which cannabis influences neural activity is
somewhat inconsistent, evidence suggests that cannabis alters striatal circuits. It is theorized that
the influence of THC on functional connectivity may be a potential mechanism by which
cannabis impacts the development of psychotic symptoms. As such, longitudinal fMRI research
in SSD samples that considers patient cannabis use during treatment is necessary to understand
the impact of cannabis on effective clinical outcomes in this population. Studies should also
control for the medication type and duration of previous medication exposure in order to address
the limitations of previous research.
Preliminary Data
Preliminary analyses conducted to support the present study used both
neuropsychological and fMRI data to suggest an impact of cannabis on AP treatment response,
and the ability to use established predictors of treatment response. Data collected during
neurocognitive examinations compared three subgroups of first-episode SSD patients (N=74)
participating in a 12-week clinical trial of antipsychotic treatment: (1) Patients not meeting
criteria for CUD at baseline or follow-up (CUD-Never; n=34); (2) Patients meeting criteria for
CUD at baseline but not follow-up (CUD- Remit; n=26); and (3) Patients who met criteria for
CUD at both time-points (CUD- Chronic; n=14). Using data from patients’ pre-and-post
neurocognitive batteries, an analysis of variance (ANOVA) revealed that improvements in
working memory performance, a common domain of impairment for SSD patients, were limited
to those who never met criteria for CUD and those that discontinued cannabis use over the
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course of treatment. This finding suggests that cannabis use during antipsychotic treatment may
hinder improvements in executive functioning controlled by frontal neural networks
(Unpublished data).
Furthermore, preliminary imaging analyses, which have since been accepted for
publication (Blair Thies et al., 2020), conducted for the current proposal examined whether CUD
impacted the established relationship between baseline SCI and AP treatment response in a
sample of 41 patients with SSD, the same sample used in the original development of the
SCI. The sample was divided into patients with a prior diagnosis of CUD (N = 17) and patients
with no prior history of CUD (N = 24), as measured by a semi-structured diagnostic interview.
Logistic regressions were conducted for both groups separately with treatment response as the
binary outcome variable. The magnitude of the effect size for those without a CUD diagnosis at
baseline, β = -2.27, OR = 0.10, was very large, which matches the results of the original findings.
The large negative β for SCI implies that lower baseline SCI predicts better odds in favor of
response. However, for those with a CUD diagnosis, the magnitude of the effect of SCI on
treatment response was much smaller β = -0.23, OR = 0.80 (Figure 4). The effect size for the
model of patients without CUD was significant and much larger (r2 = 0.86, p < 0.0001)
compared to the effect size for the model with CUD (r2 = 0.20, p = 0.10). Furthermore, for
patients without CUD, the SCI predicted treatment response with 91.7% accuracy, while in
patients with CUD, SCI only predicted treatment response with 52.9% accuracy. These results
suggest that cannabis use may interfere with the accuracy of SCI as a biomarker for treatment
response.
Impact of Cannabis on Antipsychotic Efficacy
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While research on the impact of cannabis on AP medication efficacy is limited, our
preliminary data is consistent with recent evidence that suggests it may impede effective clinical
response. An observational study of over 2000 first-episode patients found that cannabis use was
associated with a greater likelihood of hospital admission, and that this relationship was
mediated by the number of different APs prescribed. The authors proposed that a higher number
of unique APs may be considered a proxy measure of treatment non-response as it indicates there
was a clinical judgment of antipsychotic failure (Patel et al., 2016). They suggest that cannabis
use may be associated with worse clinical prognosis because of its contribution to failed AP
treatment and assert the necessity of understanding the extent to which cannabis interferes with
AP medication.
In line with this suggestion, a recent study in mice found that exposure to THC in mice
reversed the neurobehavioral effects of risperidone by reducing the brain concentrations of
risperidone and its active metabolite, 9-hydroxy risperidone. The authors demonstrate that this
reduction was mediated by THC increasing an ABC transporter, P-glycoprotein, which removes
risperidone and its metabolite from brain tissue. The findings suggest that THC increases the
amount of the compound responsible for metabolizing antipsychotic medications, allowing it less
time to be effective. Interestingly, THC does not have the same impact on the efficacy of
clozapine, another type of AP medication, because P-glycoprotein does not have an affinity to
break down clozapine as it does for risperidone (Brzozowska et al., 2017). Studies in human
subjects are necessary to understand how cannabinoids impact drug metabolism and
antipsychotic efficacy for patients.
Gaps in Previous Research
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Despite evidence that cannabis is among the most commonly used substance in patients
with SSD, its impact on cognitive and neural predictors of treatment response has not been
studied in clinical samples. Without empirical research, clinicians are limited in the
recommendations they can make to the 30-40% who report concurrent cannabis use during
treatment and the generalizations of biomarkers to predict treatment response is uncertain.
To date, no published studies have used both neurocognitive data and fMRI to investigate
the potential impact of cannabis use on demonstrated markers of AP treatment response in firstepisode SSD patients. As described above, previous research suggests that neuropsychological
functioning and striatal connectivity integral to treatment response is impacted by cannabis use
in a pattern opposite to the direction associated with psychotic symptom reduction. To address
limitations of previous research, this study will use neurocognitive indices and resting state
functional connectivity (RSFC) of the striatum to address this question in a sample of
medication-naive, uniformly treated first-episode SSD patients. While cross-sectional research of
cannabis’ impact on neural structures in non-psychotic samples has been extensive, the proposed
study will address gaps in the literature about how cannabis impacts brain functioning in SSD
patients. The acquisition of RSFC data will provide innovative information about striatum’s
functional connections above and beyond the prior research on how its structure may be
impacted by cannabis. Furthermore, exploratory analyses may be able to take advantage of the
longitudinal design of the parent study to innovatively investigate cannabis’ impact on
neuropsychological functioning and striatal networks in relation to treatment response. Our aims
are as follows:
Primary Aims
Aim 1
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The first aim is to determine the extent to which cannabis use influences differences in
neuropsychological functioning in first-episode, medication-naïve SSD patients. We will
examine the relationship between cannabis use prior to AP treatment and baseline
neuropsychological functioning, specifically attention, working memory, verbal memory, and
reasoning/problem-solving because of their prior demonstration as predictors of AP response.
We hypothesize that patients with greater cannabis use will demonstrate weaker
neuropsychological functioning prior to treatment based on findings that demonstrated impaired
cognition in SSD patients with ongoing, heavy cannabis use.
Aim 2
The second aim is to determine the extent to which cannabis use influences differences in
striatal connectivity in first-episode, medication-naïve SSD patients because of the prior
evidence of its ability to predict AP treatment response. We will examine the relationship
between cannabis use prior to treatment and baseline striatal connectivity. We hypothesize that
patients with greater cannabis use will demonstrate lower SCI prior to treatment based on prior
research that demonstrates THC-induced attenuations of striatal connectivity.
Exploratory Aims
If a sufficient number of patients complete clinical and neuropsychological ratings post
12 weeks of AP treatment, we will utilize the unique longitudinal study design to conduct
exploratory analyses that examine the potential influence of cannabis on cognitive and neural
markers of clinical outcomes.
Exploratory Aim 1
The first exploratory aim is to determine the extent to which cannabis use during
antipsychotic treatment moderates the previously demonstrated relationship between baseline
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neuropsychological functioning and treatment response in first-episode, medication-naïve SSD
patients. We will examine the interaction of cannabis use during treatment and baseline
neuropsychological function capacity on treatment response. We hypothesize that greater
cannabis use during treatment will decrease the strength of the relationship between
neuropsychological functioning and antipsychotic treatment response based on observed
differences in cognition as related to cannabis use.
Exploratory Aim 2
The second exploratory aim is to determine the extent to which cannabis use during
antipsychotic treatment moderates the previously demonstrated relationship between baseline
striatal connectivity and treatment response in first-episode, medication-naïve SSD patients. We
will examine the interaction of cannabis use during treatment and baseline resting-state striatal
connectivity on treatment response. We hypothesize that greater cannabis use during treatment
will decrease the strength of the relationship between striatal connectivity and antipsychotic
treatment response based on evidence that cannabis influences the striatal circuitry being utilized
as a predictor.
Approach
This study used a cohort of uniformly treated, medication-naïve first-episode SSD
patients recruited from an ongoing treatment study (R0I MH108654; PI: Anil Malhotra). The
parent study was originally designed to: (1) validate use of the SCI as a prognostic biomarker for
treatment response; and (2) examine longitudinal changes in the SCI as related to psychotic
symptom improvement. As part of their participation in the parent study, patients diagnosed with
SSD were treated with a single AP (risperidone) and underwent two neurocognitive batteries and
two fMRI scanning sessions at baseline and post-12 weeks of the AP trial to collect data on
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neuropsychological functioning and resting-state functional connectivity (RSFC). The 12 week
duration was based on previous research indicating that by 12 weeks of treatment, a significant
proportion of variance in treatment response is captured while also avoiding effects of attrition
(Correll, Malhotra, Kaushik, McMeniman, & Kane, 2003; Gallego et al., 2011).
Neuropsychological functioning and RSFC will be utilized to examine the extent to which
cannabis use during AP treatment influences neuropsychological indices and striatal connectivity
previously associated with treatment response. A striatal connectivity index, which captures the
strength of striatum’s connectivity with other neural regions, will be calculated using the same
methodology as in its initial development (described in the Methods section of this proposal),
given the evidence for its strong sensitivity and specificity in predicting AP treatment response.
The current analyses took advantage of the strong parent study design to examine the
extent to which cannabis use prior to treatment influences neurocognitive and RSFC markers of
treatment response and symptom reduction. The study collected detailed information on
frequency of cannabis and other illicit/non-illicit (e.g. nicotine and alcohol) substance use
immediately prior to and during the course of treatment by administering a Timeline Followback
Interview (TLFB) (Robinson, Sobell, Sobell, & Leo, 2014; Sobell & Sobell, 1992) and urine
toxicology screen at three time points during the parent study: baseline, week 6 and 12.
Understanding the relationship between cannabis, cognition, RSFC and AP treatment
outcomes is crucial as legalization of cannabis becomes more widespread across the United
States. Physicians need to understand the extent to which cannabis use interacts with the
neurobiology of treatment response, in order to accurately advise their patients on potential
outcomes of using cannabis during treatment. Furthermore, as the development of biomarkers to
predict treatment response becomes an increasingly important priority, it is critical for
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investigators to consider the influence of cannabis on neural circuitry, thereby ensuring that
biomarkers are indeed generalizable to the ~35% of SSD patients who use cannabis during AP
treatment.
Methods
Participants
Participants were recruited from The Zucker Hillside Hospital (ZHH), a large acute care
psychiatric facility serving a socioeconomically and racially diverse patient population from the
New York area. Participants were patients presenting with acute first episode psychosis,
determined by a rating scale of psychosis symptomology and use of a structured clinical
interview. Patients were medication-naïve, as this provided the opportunity to assess cognitive
functioning and striatal connectivity without the potential confound of prior treatment.
Ninety-four patients were recruited for the study. Eighty completed baseline assessments
and 44 completed all three timepoints necessary for exploratory analyses. However, four
participants were removed from baseline analyses and two additional participants (six total) were
removed from exploratory longitudinal analyses because their self-reported substance use during
the TLFB interview was inconsistent with their urine toxicology screen. For Aim 1, the final
baseline sample included 76 patients. For Aim 2, 19 participants were excluded because their
resting-state fMRI data was unusable (e.g., excessive movement during the scan or early
discontinuation of scan); the final baseline sample included 58 patients.
Of the 76 patients included in Aim 1, the mean age was 24.30 (SD = 5.63) and patients
had a mean of 13.21 years of education (SD = 2.01). The sample was 51.3% male (N = 39), and
31.6% Caucasian (N = 24), 40.8% African-American (N = 31), 14.5% Asian (N = 11), and
13.2% “Other” race (N = 10).
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Of the 58 patients included in Aim 2, the mean age was 24.20 (SD = 5.68) and patients
had a mean of 13.36 years of education (SD = 2.11). The sample was 46.6% male (N = 27), and
41.4% Caucasian (N = 24), 31% African-American (N = 18), 12.1% Asian (N = 7), and 15.5%
“Other” race (N = 9).
Inclusion Criteria
Patients met the following criteria established by previous ZHH first-episode SSD
research (Schooler, Khan, Keefe, Robinson, & Kane, 2017): (1) DSM-5 criteria for a SSD
diagnosis; (2) Current positive symptoms rated ≥4 (moderate) on at least one of the following
Brief Psychiatric Rating Scale- Anchored Version (BPRS-A) (Robinson et al., 1999) items:
hallucinatory behavior, unusual thought content, and/or conceptual disorganization; (3)
Cumulative lifetime AP drug ingestion < two weeks; (4) Within age 16-30; (5) Competent to
sign informed consent; and (6) Negative pregnancy test.
Exclusion Criteria
Patients were excluded if any of the following criteria were present: (1) Neurological or
endocrine disorder; (2) Any medical condition requiring medication with known psychotropic
effects; (3) Suicidal or homicidal behavior risk; (4) Cognitive or language impairments, or other
factors compromising informed consent; (5) Contraindications to risperidone monotherapy; (6)
MRI contraindications (e.g. pacemaker, claustrophobia); and (7) Presence of substance-induced
psychosis.
Procedures
Patients provided written informed consent; if a participant was a minor, written assent
and parental written consent were required. Patients received a comprehensive baseline
psychiatric evaluation, physical exam and laboratory testing to evaluate exclusion criteria. All
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participants received treatment with risperidone using a standardized dosing schedule appropriate
for treatment of recent-onset psychosis, which was approved and monitored by the parent study
team. Data was collected by trained research assistants at ZHH who had undergone extensive
training and who participated in regular “refresher” courses to maintain inter-rater reliability and
prevent rater drift. A breakdown of study procedures is displayed in Table 1.
Clinical Assessments
Research study visits occurred at baseline (week 0), week 6 and week 12 of AP
treatment. Diagnosis was determined at baseline using the Structure Clinical Interview for Axis I
Disorders (SCID) (First, Spitzer, Gibbon, & Williams, 1997) and the Substance Use Module was
re-administered at week 12 to assess the presence of or changes to a substance use disorder since
treatment initiation. Patients were administered the BPRS-A to measure positive psychotic
symptoms (hallucinations, delusions, thought disorder) (Robinson et al., 1999), and the Clinical
Global Impressions Scale (CGI) (Guy & Bonato, 1976) to index clinical improvement. The
BPRS-A is divided into five subscales that measure facets of SSD symptomology: Thinking
Disturbance (representative of positive symptoms), Withdrawal (representative of negative
symptoms), Hostility/Suspicion, Affective, and Activation (Burger, Calsyn, Morse, Klinkenberg,
& Trusty, 1997)
Neuropsychological Assessments
Patients underwent cognitive testing at baseline (week 0) and week 12 of AP treatment.
The MATRICS Cognitive Consensus Battery (Keefe et al., 2008), designed for repeated use with
SSD populations, was administered at both visits. It is comprised of ten tests to measure seven
cognitive domains: 1) Speed of Processing (as measured by the Brief Assessment of Cognition in
Schizophrenia (BACS) Symbol Coding; Trail Making Test-Part A; Category Fluency (Animal
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Naming)), 2) Attention/Vigilance (Continuous Performance Test—Identical Pairs (CPT-IP)), 3)
Working Memory (Wechsler Memory Scale—3rd Edition (WMS-III) Spatial Span; LetterNumber Span), 4) Verbal Learning (Hopkin’s Verbal Learning Test—Revised (HVLT-R)), 5)
Visual Learning (Brief Visuospatial Memory Test—Revised (BVMT-R)), 6) Reasoning and
Problem-solving (Neuropsychological Assessment Battery (NAB) Mazes), and 7) Social
Cognition (Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT)—Managing
Emotions).
Substance Use
The Timeline Followback Interview (TLFB) (Robinson et al., 2014; Sobell & Sobell,
1992) was used to measure substance use frequency and quantity for the past 6 weeks and was
recorded at three timepoints: baseline, 6 weeks and 12 weeks. The TLFB is a widely-used
measure to evaluate substance use, found to be valid and reliable for assessing daily substance
use in adults with SSD in both inpatient (DeMarce, Burden, Lash, Stephens, & Grambow, 2007)
and outpatient treatment settings (Carey, Carey, Maisto, & Henson, 2004). A calendar of the
previous 6 weeks was shown to participants and a trained interviewer collected information on
which days substances were used. The TLFB is especially reliable when used in conjunction
with urine toxicology screening (Stasiewicz et al., 2008). Cumulative number of sessions of
cannabis use immediately prior to and during treatment was used as primary variables of interest.
To control for the effect of other substances (e.g., nicotine, alcohol, etc.), cumulative number of
uses of other illicit substances during treatment was also collected for analyses.
Urine Toxicology Screen
A urine toxicology screen to assess drugs of abuse was administered on the same day as
collection of the TLFB to corroborate self-report. The screen was administered and analyzed in
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our research laboratory by trained physicians and technicians. The presence or absence of THC
and other substances in urine was used to validate patient TLFB self-report. The participant was
excluded from analyses if self-report did not align with their toxicology results.
Neuroimaging Methods
Resting state fMRI was utilized to identify striatal circuitry related to psychotic
symptoms and their response to AP drug treatment.
Image Acquisition
MR imaging exams were conducted at the North Shore University Medical Center on a
Siemens Prisma 3.0T MRI system (procedure duration ~30 min for structural and functional
MRI). During resting state MRI scanning, participants were asked to close their eyes and
instructed not to think of anything in particular. MRI staff checked in with participants between
scan sequences to ensure alertness. Participants were given head/back support to minimize
motion; earplugs and noise dampening headphones were provided. Each session started with
structural image acquisition, including a sagittal localizer, a high resolution T1-weighted 3D
spoiled gradient (SPGR) with 1mm slice sequence (TR = 7.5 ms, TE = 3 ms, matrix = 256x256,
FOV = 240 mm). The rs-fMRI scan utilized a gradient echo, echoplanar (EPI) sequence sensitive
to the blood oxygen level dependent (BOLD) signal, acquiring 30 slices in the AC-PC
orientation (TR=1500ms, TE=30ms, matrix = 64*64, FOV = 220mm, 26 contiguous 4mm ACPC aligned axial slices. A total of 300 EPI volumes were obtained during two 7-minute runs
(TR=2000ms, TE=30ms, matrix = 64*64, FOV=240mm, 40 contiguous 3mm axial oblique
slices). Resting-state scans that are 14 minutes long are shown to demonstrate strong test-retest
reliability of functional connectivity patterns across the brain (Birn et al., 2013; GonzalezCastillo et al., 2014; Mejia, Nebel, Barber, Choe, & Lindquist, 2016).
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Motion Effects
Rigorous quality control methods were conducted to assess each scan for motion effects.
As resting-state fMRI is susceptible to motion artifact (Power, Barnes, Snyder, Schlaggar, &
Petersen, 2012), stringent criteria were implemented during EPI preprocessing in line with
current standards (Power, Schlaggar, & Petersen, 2015). Framewise displacement (FD), a
technique that computes head motion as a scalar quantity by using a formula provided in Powers
et al. (Power et al., 2012) was applied to rigid body parameters. [dix diy diz αi βi γi]. Additionally, a
DVARS will be calculated (‘D’ referring to the temporal derivative of time courses and VARS
referring to root mean square variance over voxels) to measure rate of BOLD signal change at
each data frame. We used two parallel approaches: (1) Censoring method (“scrubbing”), which
removes volumes with FD>.02 mm to exclude patients with <70% usable volumes. Efficacy of
this de-noising method was assessed by inspecting post-de-noising time series, testing
FD/DVARS-functional connectivity correlations for non-significance and adding a group
movement variable to analysis; and (2) Without applying any de-noising method, mean FD was
used as a regressor of no interest across participants. Previous studies by our group have not
observed significant differences between patient subgroups (responders versus nonresponders),
suggesting our cannabis regressor of interest will not be collinear with motion (Argyelan et al.,
2014).
Resting-state Pre-processing Pipeline
After removal of the first four scans (for magnetic equilibration), skull- stripping (using
BET (Smith et al., 2004)), initial high- and low-pass filtering and motion correction as described
immediately above, the resulting data was smoothed with a 6mm Gaussian kernel. Time series
from the predefined regions of interests (seeds, as defined in sections below) were extracted by
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AFNI scripts. We utilized these time series to calculate voxel-wise Pearson correlations across
the whole brain, resulting in individual-based, seed-specific correlation maps. The preprocessed
resting-state fMRI images also served to calculate registration matrices from the functional space
to the co-planar T2, then to the SPGR and then to the MNI brain. We used these registration
matrices to transform correlation maps from functional space to MNI space and conduct a
Fisher’s Z transformation to compare the resulting correlation values between groups.
Additionally, data was analyzed with and without global mean scaling.
RSFC Analyses
Our primary goal in Specific Aim 2 was to examine differences in striatal connectivity as
related to cannabis use, and Exploratory Aim 2 characterized the interaction of cannabis and
striatal connectivity as related to treatment response, given the previous evidence for cannabis
altering striatal activity. Based on methods previously employed by the parent study team, the
SCI was computed (Sarpal et al., 2016) to define striatal connectivity as follows: Whole-brain
functional connectivity maps were generated for each subject based on seeds placed in DS and
VS subregions as defined by Di Martino and colleagues (Di Martino et al., 2008). A 3.5 mm
spherical regions of interest was created in the dorsal caudate, ventral caudate, nucleus
accumbens, dorsal rostral putamen, dorsal caudal putamen and ventral rostral putamen. These
striatal RSFC maps were entered into a voxel-wise survival analysis using our strict definition of
treatment response. RSFC values from significant striatal connections were combined to form
SCI, after normalization and weighting of connectivity values.
Statistical Analysis
Sample Size and Power Analysis
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A power analysis was conducted using GPower (v3.1) and confirmed that a sample size
of 58 would provide sufficient power to detect large effect sizes. The effect-size measurement
we used for power analysis was Cohen’s f (Cohen, 1988), considered an appropriate effect size
measurement for multiple regression (Selya, Rose, Dierker, Hedeker, & Mermelstein, 2012).
Based on Cohen’s benchmark, f = 0.02 is considered small, 0.15 medium and 0.35 large. At 5%
significance level, and 80% power, GPower calculated that a sample size of 58 would be able to
detect f = 0.375, which is a large effect size based on Cohen’s benchmark. This estimation is
consistent with previous RSFC studies that have used 15–20 subjects to demonstrate significant
main effects (Honey et al., 2003; Kelly et al., 2009; Ramaekers et al., 2013; Schrantee et al.,
2016). For our exploratory aims, GPower calculated that a sample size of 43 would be
appropriate to detect an interaction effect. If pre-and-post data is collected on at least 43 patients,
our exploratory analyses will be conducted.
Primary Aims
For both aims, we evaluated cannabis use during treatment as both a continuous and
categorical variable. As a continuous variable, cannabis use during treatment was defined as the
cumulative number of cannabis use sessions in the 6 weeks prior to treatment as measured by the
baseline TLFB administration and confirmed by urine screen. As a categorical variable, we
divided participants into non-users, occasional users (i.e., those who had used cannabis between
1-29 times in the 6 weeks prior to treatment), and heavy users (i.e., those who had used cannabis
30 or more times in the 6 weeks prior to treatment, indicating daily or near daily use) based on
prior cannabis use research (Asbridge, Duff, Marsh, & Erickson, 2014).
The TLFB was chosen to operationalize cannabis use given its wide use and strong
validity and reliability in SSD samples. While urine screening is a reliable method to detect
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cannabis use, THC levels and the timeframe in which it is detected varies based on fluid intake,
timing of last use, and personal metabolism (Lum & Mushlin, 2004). Because the interim
between screens is six weeks, we were concerned that, for example, someone who reports using
daily in the 4-6 weeks prior to the scan will show lower drug levels than someone who smoked
once two days prior. Thus, the TLFB best captured the full extent of drug use regardless of the
timing of use. Baseline SCI was a continuous variable defined by the previously described
procedures. Prior to conducting the primary analyses, an examination of correlations between
cannabis use and other illicit substances (alcohol, nicotine, or other drug use) was conducted to
check for potential confounding effects of polysubstance use. If significant, these variables were
included as covariates in regression analyses. While rates of nicotine use are known to be
significant in SSD patients, prior research does not find differences in nicotine use between
cannabis users and non-users and thus, it will be important to do a statistical check prior to
including it as a covariate in analyses (Fowler, Carr, Carter & Lewin, 1998). Additionally, prior
research has found that cannabis-using patients with and without concurrent illicit substance use
(e.g. amphetamines, alcohol) do not show performance differences on neuropsychological tasks
(Yucel 2012).
Primary Aim 1. We focused on cognitive functions previously seen to be impaired in
SSD populations, specifically learning, explicit memory, attention, working memory and
reasoning and problem-solving. Raw scores from the MCCB are standardized by age and sex
into T-scores for each cognitive domain it evaluates. To evaluate the influence of cannabis as a
continuous variable, five linear regressions were performed to examine the relationship between
cannabis and our neurocognitive domains of interest: 1) working memory, 2) reasoning and
problem-solving, 3) attention, 4) verbal learning and 5) visual learning. The cumulative number
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of cannabis use sessions prior to treatment was entered as the predictor variable in all models,
along with age and sex as covariates. The baseline performance scores for each cognitive domain
was entered as outcome variables in the separate models. To evaluate cannabis as a categorical
variable, an ANOVA was conducted to compare significant differences in means between nonusers, occasional users, and heavy users on baseline performance of each neurocognitive domain.
Primary Aim 2. To evaluate the influence of cannabis as a continuous variable, a linear
regression was performed to examine the relationship between cannabis and baseline SCI. The
cumulative number of cannabis use sessions prior to treatment was entered as the predictor
variable. The SCI is a continuous variable defined by the previously described procedures and
was entered as the outcome variable. Age and sex were used as covariates given the significant
neural changes that occur during the typical age of onset for SSD (i.e. adolescence and young
adulthood) and potential sex-based neural differences. To evaluate cannabis as a categorical
variable, an ANOVA was conducted to compare significant differences in mean baseline SCI
between non-users, occasional users, and heavy users.
Exploratory Aims
Exploratory analyses were ultimately not conducted due to an insufficient number of
patients with available longitudinal data but they are outlined below to describe the original
aims. However, independent sample t-tests and chi-square tests were conducted to evaluate
differences between responders and non-responders. Scatterplots were created to evaluate for
potential interaction effects between cannabis, neurocognitive functions, and the SCI in relation
to treatment response.
For both exploratory aims that examine the influence of cannabis on longitudinal clinical
outcomes of AP treatment, treatment response was assessed as a binary (response/non-response)
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variable defined a priori as meeting the following criteria at week 12 of AP treatment: (1) a
rating of 3 (mild) or less on the following items of the BPRS: unusual thought content,
hallucinatory behavior, grandiosity, and conceptual disorganization; and (2) CGI improvement
rating “very improved” or “much improved”. While trajectory of AP treatment response varies
between individuals, latent class Gaussian mixture modeling has been used to demonstrate two
clear groups of responders and non-responders which supports the dichotomous characterization
of treatment response trajectory (Homan, under review). Cannabis use during treatment, a
continuous variable, was defined as the cumulative number of cannabis use sessions immediately
prior to and during treatment (as measured by the summed reports of the three TLFB
administrations and confirmed by urine screen). Logistic regressions were conducted because of
the binary nature of the dependent variable, treatment response.
Exploratory Aim 1. We planned to conduct five logistic regressions with treatment
response as the dependent variable, and cannabis use during treatment and baseline
neuropsychological functioning as independent variables. An interaction term of the two
independent variables would be included in the logistic regression model to assess the
moderation of cannabis use on the relationship between baseline cognition and treatment
response. Separate interaction terms would be computed using baseline MCCB T-scores for the
neuropsychological domains of interest (i.e. attention, working memory, reasoning and problemsolving, visual learning and verbal learning).
Exploratory Aim 2. We planned to conduct a logistic regression, with treatment
response as the dependent variable and cannabis use during treatment and SCI as independent
variables. An interaction term of the two independent variables would be included in the logistic
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regression model to assess the moderation of cannabis use on the relationship between baseline
SCI and treatment response.
Results
Exploratory analyses were not conducted due to the sample of patients with available
longitudinal data being too small to provide sufficient power with which to detect a meaningful
interaction effect. Specifically, longitudinal analyses would have only included 39 patients and
32 patients with necessary neurocognitive data and fMRI data, respectively. This would not have
provided sufficient power based on our power analysis estimates. However, independent sample
t-tests and chi-square analyses were conducted to investigate differences between responders and
non-responders, the results of which are described in this section.
Aim 1: Determine the Extent to Which Cannabis Use Influences Differences in
Neuropsychological Functioning
Participant Substance Use Patterns
Of the 76 patients included in Aim 1, 56.6% of patients (N = 43) used cannabis at least
once in the six weeks prior to baseline. Of those who used, 35.5% used occasionally (1-29 times)
and 21.1% used cannabis heavily (30 or more times). 36.8% of patients (N = 28) used nicotine,
63.2% (N = 48) used alcohol, and 7.9% (N = 6) used some other nonprescribed illicit substance
(i.e., cocaine, ecstasy, hallucinogens, stimulants, methamphetamines, or opioids).
Chi-square tests and independent sample t-tests were conducted to evaluate differences
between cannabis non-users (i.e., patients who did not use any cannabis in the six weeks prior to
their baseline assessment) relative to cannabis users (i.e., patients who used cannabis at least
once in the previous six weeks). A breakdown of results is displayed in Table 2. Cannabis users
were significantly more likely to be younger, male, and African-American. They were also
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significantly more likely to have used nicotine, alcohol and other substances at least once in the
six weeks prior to baseline. There were no differences between cannabis non-users and cannabis
users in education, and number of days alcohol and nicotine were used on in the six weeks prior
to baseline. However, cannabis users were more likely to have used a greater amount of nicotine
and alcohol on the days they used (as defined by number of cigarettes and drinks). Additionally,
while there were no differences in overall baseline symptom severity, cannabis users exhibited a
significantly greater amount of hostility/suspicion symptoms.
Independent sample t-tests were also conducted to evaluate differences between cannabis
non-users and heavy cannabis users. Similar to the comparison of cannabis non-users and general
users, heavy cannabis users showed a greater amount of hostility/suspicion symptoms, and used
a greater amount of nicotine and alcohol on the days they used (Table 3).
Regression Results
All primary variables (i.e., cannabis use, neuropsychological domains, and SCI) were
normally distributed. In addition to age and sex, average number of nicotine use per day was
included as a covariate because correlation analyses revealed a significant association between
nicotine and neuropsychological domains of interest.
When cannabis use was defined as a continuous variable, neuropsychological functioning
was not associated with the frequency of recent cannabis use for any of the five cognitive
domains evaluated (i.e., Attention and Vigilance (p = .75, r = .23, F = .95, β = -.04), Working
Memory (p = .79, r = .35, F = .2.42, β = .03), Verbal Memory (p = .64, r =.32, F = 2.01, β = .06), Visual Memory (p = .39, r = .32, F = 1.98, β = .11), and Reasoning and Problem Solving (p
= .85, r = .39, F = 3.22, β = -.02)). Of note, average number of nicotine uses per day had a
significant effect on working memory (p = .004, β = -.36), verbal memory (p = .03, β = -.26), and
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visual memory (p = .04, β = -.26) in that a greater amount of nicotine use per day was associated
with weaker cognitive functioning in these domains.
When cannabis use was defined categorically (i.e. non-users, occasional users, and heavy
users), there was also no significant difference between groups on any of the cognitive domains
assessed (i.e., Attention and Vigilance (p =.56, F = .59), Working Memory (p = .88, F = .13),
Verbal Learning (p = .43, F = .85), Visual Learning (p = .89, F = .12), and Reasoning and
Problem Solving (p = .50, F = .71)).
Exploratory independent sample t-tests and chi-square tests to compare differences
between AP responders and non-responders revealed that there were no significant differences
between responders and non-responders in regard to neuropsychological performance, or use of
cannabis, nicotine, alcohol or other drug use immediately before and over the course of AP
treatment (Table 4).
Post-hoc analyses were conducted to compare neuropsychological differences post-12
weeks of treatment between patients who did not use cannabis before or during treatment (NonUsers, N = 19), patients using cannabis at baseline who remitted during treatment (Remitters =
9), and patients who used cannabis at baseline and throughout treatment (Persistent Users = 10).
A one-way ANOVA revealed a significant difference between groups on Reasoning and Problem
Solving performance, in that Persistent Users had the strongest functioning in this domain (Mean
= 48.60, Standard Deviation (SD) = 11.85) relative to Non-Users (Mean = 45, SD = 12.08) and
Remitters (Mean = 34.33, SD = 12.29).
Aim 2: Determine the Extent to Which Cannabis Use Influences Differences in Striatal
Connectivity
Participant Substance Use Patterns
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Of the 58 patients included in Aim 2, 55.2% of patients (N = 32) used marijuana at least
once in the 6 weeks prior to their baseline fMRI scan. 34.5% of patients (N = 20) had used
nicotine, 60.3% (N = 35) had used alcohol, and 6.9% (N = 4) used some other nonprescribed
illicit substance (i.e., cocaine, ecstasy, hallucinogenics, stimulants, methamphetamines, or
opioids). Chi-square tests and independent sample t-tests were conducted to evaluate differences
between cannabis non-users relative to cannabis users. A breakdown of results is displayed in
Table 5.
Similar to demographic patterns observed in the Aim 1 sample, cannabis users were
significantly more likely to be younger, male, and African-American. They were also
significantly more likely to have used nicotine and alcohol at least once in the six weeks prior to
baseline, and to have used nicotine a greater number of days over the prior six weeks before
treatment. However, there was no differences in the average amount of nicotine or alcohol used
per day between cannabis non-users and cannabis users. There were also no differences in years
of education or overall baseline symptom severity. While there were no differences in overall
baseline symptom severity, cannabis users exhibited a significantly greater amount of
hostility/suspicion symptoms.
Independent sample t-tests were also conducted to evaluate differences between cannabis
non-users and heavy cannabis users which revealed that heavy cannabis users showed a greater
amount of hostility/suspicion symptoms and negative symptoms (Table 6).
Regression Results
When cannabis use was defined as a continuous variable, baseline SCI was not associated
with recent cannabis use (p = .83, r = .17, F = .37, β = -.08). When cannabis use was defined
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categorically, there was also no significant difference of the SCI between non-users, occasional
users, and heavy users (p = .86, F = .15).
While there was not a large enough sample to conduct exploratory analyses, independent
sample t-tests and chi-square analyses to evaluate differences between responders and nonresponders revealed that responders had a higher SCI at baseline relative to non-responders.
They also used nicotine more days than non-responders. There were no significant differences
between responders and non-responders in regard to cannabis, alcohol, or other drug use
immediately before and over the course of AP treatment (Table 5). Additionally, a scatterplot
revealed that the relationship between cannabis use and the SCI was different for responders and
non-responders, suggesting a potential interaction effect may be detectable when more patients
are included in the analyses (Figure 5). Specifically, the graph illustrated that for patients who
responded to AP treatment, lower baseline SCI was associated with less cannabis use prior to and
over the course of AP treatment, while for non-responders, lower baseline SCI was associated
with a greater amount of cannabis use prior to and over the course of treatment. A post-hoc
analysis divided the sample into responders and non-responders, and used a linear regression to
evaluate the impact of cannabis use on the SCI. Baseline cannabis use was entered as the
predictor variable and the SCI was entered as the outcome variable. The results demonstrated
that for non-responders, there was a significant negative relationship between baseline cannabis
use and the SCI (p = .005, β = -.802) whereas there was no significant relationship for responders
(p = .28, β = .25). This suggests that cannabis use may differentially affect the SCI for
responders and non-responders.
Discussion
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This study evaluated the extent to which cannabis influences previously demonstrated
neurocognitive and neuroimaging biomarkers of antipsychotic treatment response in medicationnaïve first-episode SSD patients. Results demonstrate first, that neurocognitive functions
previously demonstrated to predict AP treatment response (specifically, reasoning and problem
solving, attention, visual and verbal learning, and working memory) were not influenced by the
amount of cannabis used in the six weeks prior to beginning AP treatment. Second, findings
demonstrated that a baseline neuroimaging measure of striatal connectivity previously
demonstrated to predict AP treatment response, the SCI, was also not influenced by the amount
of cannabis use patients used in the six weeks prior to treatment. While a small sample size
prevents us from investigating whether there was an interaction between cannabis and
biomarkers in predicting treatment response, there was evidence to suggest that the relationship
between the SCI and cannabis may be different for responders and non-responders. The
implications of such an interaction are discussed in the “Cannabis and SCI” section.
Cannabis and Neuropsychological Functioning
Our findings suggest that cannabis does not influence the neuropsychological domains
that have been previously demonstrated to predict treatment response for patients with SSD:
attention, working memory, verbal and visual learning, and reasoning and problem solving. Our
results did not support our hypothesis that patients with greater cannabis use prior to treatment
would demonstrate weaker neuropsychological functioning. In fact, post-hoc analyses revealed
that patients who kept using cannabis throughout AP treatment had stronger neuropsychological
functioning post-12 weeks of AP treatment compared to non-users or patients who stopped
using.
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Our results are in contrast to prior research that indicates a dose-response relationship
between cannabis use and neuropsychological functioning in SSD (Núñez et al., 2016) and nonSSD individuals (Curran, Brignell, Fletcher, Middleton, & Henry, 2002). Indeed, even at very
heavy levels of use (i.e., greater than or equal to 1x/day), there did not appear to be a significant
difference in neuropsychological functioning in our sample. However, our findings are
consistent with previous studies that found no differences in neuropsychological performance
between patients who are cannabis users and those who are not (Schoeler et al., 2016a; Sevy et
al., 2007) in both first episode SSD (Yucel et al., 2012; Lesson et al., 2012, Bugra et al., 2013)
and chronic SSD samples (Rabin, Zakzanis, & George, 2011; Løberg & Hughdal, 2009).
Additionally, our results showed that patients who continued using throughout treatment
demonstrated stronger neuropsychological functioning at 12 weeks post-treatment which is also
consistent with previous findings that cannabis using patients are cognitively superior (JockersScherubl et al., 2007; Schnell et al., 2009).
The unexpected association between stronger cognitive functioning and cannabis use in
SSD patients might be explained by several extant hypotheses. One hypothesis posits that
cannabis-using patients have stronger cognitive and social skills that enable them to acquire and
sustain their drug use (Potvin et al., 2008). However, this might obscure the “true” effect of
cannabis on cognition because such patients are starting out at a higher level of cognitive
functioning relative to non-using patients. Another hypothesis suggests that cannabis-using SSD
patients may belong to a subgroup of patients who are neurocognitively less vulnerable to
developing psychosis but whose early onset of regular cannabis use may have triggered
psychosis. In other words, this theory surmises that there is a subgroup of patients who would
have been asymptomatic, or remained asymptomatic for longer, had it not been for their early
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initiation of cannabis use, and thus, prior to their illness may have looked more neurocognitively
typical. It also suggests that when neurocognitively typical individuals use a heavier “load” of
cannabis, there is a lower threshold for the vulnerability required to manifest psychotic
symptoms (Schnell et al., 2009). This hypothesis has been supported by research findings
indicating that 1) the neurocognitive profile of SSD patients is different depending on the age of
onset of cannabis use, with patients who begin using earlier in life having superior cognition, 2)
that early onset of cannabis use in adolescence is associated with a higher risk for development
of an SSD (Areneault et al., 2002; Yucel et al., 2012), 3) that more frequent cannabis use is
associated with stronger cognition (Schnell et al., 2009), and 4) that cannabis acutely exacerbates
psychosis and impairs cognition in individuals at CHR for psychosis (Vadhan et al., 2017).
Other theories have focused on the neural impact cannabis has on the brain to explain the
potentially beneficial effect of cannabis for schizophrenia patients’ cognition, suggesting a
neuroprotective effect of cannabis. These theories point to research that has demonstrated
neuroprotective capacities of cannabinoids including antioxidant, anti-inflammatory, antiexcitotoxic, and anxiolytic properties that provide neuroprotection against neurodegenerative
disorders. Cannabinoids have also been demonstrated to protect against neurotoxicity in cellular,
animal and human research (Ritsner, 2010).
Additionally, attention and executive function impairments in SSD have been associated
with decreased prefrontal acetylcholine, serotonin, dopamine, noradrenaline, glutamate, and
GABA (Benes et al., 1996; Clarke et al., 2004; Coyle, 2004; Dalley et al., 2002; Friedman et al.,
1999; Sarter and Bruno, 1999; Zavitsanou et al., 2002). THC has been demonstrated to increase
prefrontal amounts of these neurotransmitters, providing support for the hypothesis that this may
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be a mechanism by which patients gain a cognitive benefit from cannabis (Jentsch et al., 1996;
Acquas et al., 2001; Ferraro et al., 2001; Coulston et al., 2007).
Studies have also found that some neurotrophins such as nerve growth factor and brainderived neurotrophic factor (BDNF) are found in greater quantities in cannabis-using
schizophrenia patients compared to those who are not using. This has led researchers to theorize
that ongoing cannabis use may promote endogenous neural growth and even neurogenesis that
compensates for the existing neural deficits of SSD patients, offering a neuroprotective effect.
This difference is not seen in non-SSD samples which may explain why ongoing cannabis has
been associated with enhanced cognition in SSD patients but not in generally healthy individuals
(Jockers-Scherubl et al., 2007). This theory also does not account for why cannabis use acutely
impairs cognition.
In sum, our findings uniquely demonstrate that in a sample of largely medication-naïve
first-episode SSD patients, cognitive functioning associated with treatment response does not
appear to be influenced by cannabis use prior to treatment. While we did not have sufficient
longitudinal data to evaluate whether these cognitive functions were predictive of treatment
response in our sample, there were no differences in baseline neuropsychological functioning
between responders and non-responders. There were, however, differences between patients who
desisted cannabis use relative to those who continued using cannabis over the course of
treatment, in that those who continued using performed better on neuropsychological tests. It
should be noted that our sample size (N = 31) for this post-hoc analysis was small and should be
interpreted with caution. However, the results support the need for research on cognitive
functioning of SSD patients following abstinence from regular cannabis use. While there is
evidence that cognition can improve following abstinence from cannabis in healthy individuals,
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research on how abstinence impacts cognition for cannabis-using SSD patients is needed. It may
be that in SSD patients, the neural systems that subserve cognition become more easily
dependent on cannabis for optimal functioning and thus, are more vulnerable to decline when use
is discontinued.
Cannabis and Striatal Connectivity
Our findings indicated that the SCI was not influenced by the amount of cannabis use in
the six weeks prior to AP treatment and baseline scan. These results did not support our
hypothesis that greater cannabis use would demonstrate lower SCI prior to treatment. This is in
contrast to evidence that cannabis impacts the striatum in both animal and human studies.
Specifically, it conflicts with evidence that both acute inductions and chronic use of cannabis are
associated with aberrant resting-state functional connectivity between the striatum and the
prefrontal cortex. These differing results may be explained by neurobiological factors that
influence which individuals are susceptible to cannabis’ impact on their neural circuitry.
For example, it has been proposed that there are subtypes of SSD based on dopaminergic
functioning: a hyperdopaminergic type, characterized by elevated striatal dopamine synthesis
and release capacity, and a normodopaminergic type that does not show such alteration. If this is
true, it may be that the hyperdopaminergic type is more or less vulnerable to the dopaminealtering effects of cannabis (Howes & Kapur, 2014).
Genetic differences may also contribute to differing striatal and dopaminergic responses
to cannabis. The dopamine β-hydroxylase (DβH) enzyme transforms dopamine into
noradrenaline, and it is posited that relative to individuals with high activity DBH genotypes,
those with low activity DBH genotypes are more sensitive to the cognitive and neural influence
of cannabis on the limbic reward network because it creates a hyperdopaminergic state. A
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sample of 122 healthy (non-psychotic) drug users underwent acute inductions of cannabis and
placebo prior to undergoing a resting-state fMRI to examine functional connectivity between the
nucleus accumbens and subcortical regions. An interaction was observed between DBH
genotype and the impact of cannabis on functional connectivity; specifically, only for individuals
with low activity DBH genotypes did cannabis reduced functional connectivity between the
nucleus accumbens and striatum, limbic regions, thalamus, and prefrontal cortex (Ramaekers et
al., 2016). Results suggest that it may be that cannabis impacts corticostriatal connectivity for
only a certain genetic subset of patients.
Our exploratory analyses, which aimed to examine the extent to which cannabis use
interacted with previously demonstrated biomarkers to predict treatment response, were unable
to be conducted which limited our ability to assess cannabis’ impact on the predictive utility of
the SCI. However, a scatterplot indicated that the relationship between cannabis and the SCI
differed between AP responders and non-responders, in that there was a negative association
between cannabis and the SCI for non-responders and a positive association for responders. A
post-hoc analysis was conducted to test for statistical significance of this difference which
divided the sample into responders and non-responders. The analysis revealed that there was a
significant negative relationship between cannabis and the SCI for non-responders, while the
relationship between cannabis and the SCI for responders was not significant. It is possible that
a greater sample size may detect a significant interaction between cannabis and the SCI that
implies a moderating effect of cannabis on treatment response. Specifically, the ability for the
SCI to predict treatment response could be different depending on the level of cannabis use by
patients.
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This would align with a recently published study conducted by our group that found that
a lifetime history of Cannabis Use Disorder (CUD) moderated the relationship between SCI and
AP treatment response, such that it had little predictive value in SSD patients with a CUD history
(Blair Thies, 2020). Similar to the present analyses, this prior research demonstrated that there
were no group differences in baseline SCI between patients with and without a CUD history
despite the presence of an interaction effect. Thus, while our results demonstrate that cannabis
may not directly influence the SCI at baseline, this does not exclude the possibility that cannabis
may have a moderating effect on the SCI’s ability to predict treatment response. As our results
revealed a potential difference in the relationship between cannabis and the SCI for responders
and non-responders, it will be important to collect further longitudinal data to clarify whether
this has implications for the SCI’s predictive utility as has been seen previously.
Limitations and Future Directions
Our study is limited by several factors that will be critical to include in future research on
the relationship between cannabis and biomarkers of treatment response.
Heterogeneity of Cannabis Composition
Our results are limited by the lack of data on the specific type of cannabis used by our
patient sample, specifically the proportion of THC and cannabidiol (CBD). Cannabis sativa
extract is comprised of over 60 different types of cannabinoids, with THC and CBD being the
most prominent (Müller-Vahl & Emrich, 2008). While it has been demonstrated that firstepisode patients are more likely to use strains of marijuana that have a significantly greater
proportion of THC relative to CBD (Di Forti et al., 2009), we were unable to collect this
information in our sample. Though a meta-analysis published in 2012 indicated that there had
been a consistent increase in cannabis potency (i.e. a higher proportion of THC relative to CBD)
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globally over the past three decades (Cascini, Aiello and Di Tanna, 2012), over the course of
data collection for this study, legalization and decriminalization of marijuana expanded
significantly across the United States, including in New York. This has made for a highly
diversified market of marijuana products that offer heterogenous ratios of THC to CBD and
greatly increased global use of CBD-dominant products during a portion of data collection
(Brightfield Group, 2018). Varying concentrations of CBD and THC in the cannabis used by our
sample may make detection of an effect difficult as prior research suggests that THC and CBD
appear to have opposite effects on both cognition and striatal functioning in healthy individuals
(Morgan et al., 2012; Bhattacharyya et al., 2015; Winton-Brown et al., 2011). It has also been
demonstrated that CBD may counteract the detrimental cognitive and psychiatric effects of THC
in healthy and SSD individuals (D’Souza et al. 2005; Morgan et al., 2010).
For example, in a study that investigated how cognitive processing in cannabis users
varied as a function of CBD content, Morgan et al. (2010), examined differences in performance
on a verbal memory task when participants were given low-CBD versus high-CBD cannabis;
both types of cannabis had the same amount of THC. The study found that participants in the
high-CBD group demonstrated stronger performance on the verbal memory task compared to the
low-CBD group. Their results suggest that the presence of CBD attenuated the detrimental
impact caused by acute THC inductions (D’Souza et al. 2005; Morgan et al., 2010). Furthermore,
they found that cannabis users who typically used high-THC cannabis evidenced disrupted
verbal and episodic memory while those who used high-CBD cannabis exhibited stronger
recognition memory (Morgan et al., 2012). A study done by Englund et al. (2013) found that
when individuals were pretreated with CBD or placebo prior to an intravenous THC-induction,
the placebo group exhibited weaker verbal and working memory performance following THC
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administration. Taken together, these findings provide support for the idea that memory
disruption is more likely for individuals using cannabis that has a high THC/low CBD
composition, and that the presence of CBD may provide a protective effect against the
detrimental cognitive impact of THC (Englund et al., 2013).
Neuroimaging studies have also revealed differential effects of THC and CBD on neural
circuitry involved in cognition, including the striatal network. Specifically, inductions of THC
and CBD have been found to have opposite effects on striatal, prefrontal, hippocampal, and
cerebellar activity during cognitive tasks (Bhattacharyya et al., 2015; Winton-Brown et al.,
2011). In a study of healthy individuals that compared the neural effects of THC, CBD, and
placebo inductions on functional connectivity during a salience processing task, THC reduced
fronto-striatal connectivity while CBD enhanced connectivity between these regions. In contrast,
THC enhanced mediotemporal-prefrontal connectivity while CBD reduced connectivity of these
networks. These changes were associated with an acute increase in psychotic symptoms, as well
as with impaired neurocognitive performance (Bhattacharyya et al., 2010; Bhattacharyya et al.,
2015). While additional induction research is needed in patients with SSD, it may be that CBD
and THC have similarly opposing effects as is seen in healthy individuals.
In sum, it could be that the lack of a relationship between cannabis and
neuropsychological performance, and SCI in the present study would make sense if patients were
using forms of cannabis with relatively low THC/CBD ratios. Future research should attempt to
control for the impact of various proportions of THC and CBD through randomized controlled
trials, given the differences in their cognitive and neural impact. Greater understanding of the
differential impact of THC and CBD on brain activity and function will help mental health
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practitioners provide accurate guidance to their patients about the effect of their personal
cannabis use.
Lack of Control for Variables Related to Lifetime and Current Patterns of Use
Our results are also limited by the lack of data on certain aspects of cannabis use that
could have impacted cannabis’ effect (or lack thereof). For example, we do not have information
on the specific methods by which people smoked marijuana, such as by traditional or electronic
cigarettes. Over the three years of data collection for this study, use of electronic cigarettes and
vaporizers increased dramatically nationwide (NIDA, 2020). As much as possible, information
was collected about the brand of cannabis or nicotine oil used and frequency of “hits” in order to
estimate the equivalent number of cigarettes or cannabis used. However, given that the
cannabinoid content/ratios may be misrepresented by sellers (Vandrey et al. 2015), and research
on the differences between traditional cigarettes and electronic cigarettes is limited (Warner &
Mendez, 2019), these potential effects remain unclear.
Additionally, while we evaluated the number of total sessions patients used cannabis over
the six weeks prior to treatment, we did not include information on how recently patients used
cannabis prior to their baseline neuropsychological evaluation and neuroimaging scan which
could have impacted our results. It has been demonstrated that cognitive impairment is most
prominent after persistent cannabis use and thus, patients who used marijuana in the days
immediately prior to baseline assessments versus those who used six weeks prior may have
performed differently (Meier et al., 2012). There is also evidence that the negative impact of
THC on cognition resolves after abstinence and thus, could have gone undetected in our sample
for patients who last used cannabis further before baseline assessments, thereby explaining the
lack of impact. For example, Pope et al. (2001) demonstrated that in non-SSD cannabis users,
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cognitive deficits recover after four weeks of abstinence. Another study that investigated
cerebral blood volume (CBV) over 28 days of abstinence in chronic users found that CBV
aberrancies normalized with continued abstinence (Sneider et al., 2008).
We also did not collect data on other important variables regarding individual patterns of
cannabis use such as age at initial use, duration of cannabis use, and exact amount of cannabis
consumption. It will be critical for future research to include this information in order to better
understand moderating factors that may make cannabis use more or less detrimental for patients.
Confounding Effects of Nicotine
Our results are also limited by the confounding effect of nicotine on the relationship
between cannabis and previous neurocognitive markers of treatment response. Specifically,
while there was no impact of cannabis on our neurocognitive domains of interest, when nicotine
was included as a covariate, we found that it was associated with weaker working memory,
verbal memory and visual memory.
The impact of cannabis and tobacco on SSD patients is often intertwined, as rates of
comorbid tobacco and cannabis use are substantial in SSD samples (de Leon & Diaz, 2005;
Hughes et al., 1986). Studies have reported that up to 90% of cannabis users also smoke tobacco,
substantially higher than co-use rates between cannabis and other substances (e.g., alcohol or
cocaine) (Barrett, Darredeau, & Pihl, 2006). In our sample, 51.2% of cannabis users also used
tobacco. These high rates complicate research on the impact of tobacco and cannabis use’s effect
on neuropsychological functioning, as each substance appears to have opposite effects on
cognition (Rabin & George, 2015).
Nicotinic receptor systems are involved in important cognitive functions, namely learning
memory, and attention (Levin & Rezvani, 2007). Nicotinic receptor deficits in the frontal cortex
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and hippocampus are observed in the brains of individuals with SSD, which are theorized to
contribute to the cognitive symptoms of the disease (Durany et al., 2000; Freedman, Adams, &
Leonard, 2000). Nicotine administration through a variety of delivery methods (e.g., skin
patches, nasal spray) has been found to improve attention, working memory and learning in
patients with SSD (Arendash et al., 1995; Dalack, Healy, & Meador-Woodruff, 1998; Levin &
Christopher, 2002). Thus, it was surprising that in our sample, we found weaker cognitive
functioning in these domains to be associated with greater tobacco use.
Our results may be explained by cannabis having a “neutralizing” effect on the typical
cognitive-enhancing effect of nicotine. While research in psychotic samples is limited, in nonpsychotic populations, acute nicotine and cannabis use appear to induce opposite effects on
cognition (Rabin & George, 2015). While nicotine enhances attention and memory, cannabis
reduces concentration, learning, and memory. One preclinical study that examined the effects of
pre-treating mice with the cannabinoid receptor antagonist, AM251, versus the cannabinoid
receptor agonist, WIN55 212-2. Their results found that both type of cannabinoid binding prior
to injections of nicotine significantly prevented nicotine-induced memory enhancement relative
to nicotine inductions alone (Biala & Kruk, 2008). Another study by Jacobsen et al. compared
healthy adolescent users of tobacco and cannabis to healthy adolescent tobacco-only users on
tasks of verbal learning and memory during an fMRI scan. They found that among cannabis
users, nicotine withdrawal led to reduced verbal delayed recall and disruption of frontoparietal
connectivity; this effect was not seen in the tobacco-users only group. Their results suggest that
concurrent cannabis use may impair cognitive processes (and the networks that subserve them)
that are otherwise protected by tobacco use on its own (Jacobsen et al., 2007).
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In sum, the confounding effect of comorbid tobacco use in our sample limits conclusions
we can draw about the specific effects of cannabis on cognition. Though more research is
needed, it may be that tobacco use attenuates cognitive impairment in cannabis users and may
provide a neutralizing effect to cause cognitive functioning to be in its normal state. It is possible
that in our sample, because marijuana use was more common and more frequent than tobacco
use, that the typical cognitive-enhancing effect of nicotine was not substantial enough to override
a potentially cognitive-impairing effect of cannabis. While more research in this area is
necessary to understand the neural interaction between nicotine and cannabis in SSD
populations, and how this relates to cognitive symptoms, it is certainly possible that comorbid
tobacco use may have influenced our results to some extent.
Strengths
Despite these limitations, this is the first study to use both neuropsychological and fMRI
measures to evaluate the impact of cannabis on previously demonstrated cognitive and neural
markers of treatment response in patients with SSD. Our use of a first-episode sample that all
had less than 2 weeks lifetime exposure to AP drugs reduced confounds of previous studies that
have 1) lacked controls for prior medication effects, and 2) used a heterogenous sample of
patients at differing stages of their illness (i.e., first-episode versus chronic SSD). Our results are
also strengthened by our ability to evaluate marijuana as both a continuous and categorical
variable, as well as our ability to control for other types of substances such as nicotine and
alcohol.
Conclusions and Implications
Taken together, our results suggest that cannabis does not impact previously
demonstrated neurocognitive or striatal connectivity biomarkers of treatment response. However,
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our results did provide evidence that cannabis is differentially related to the SCI for patients who
are responders versus those who are non-responders. This will be important to further investigate
to understand cannabis’ impact on the predictive utility of such biomarkers.
It should be emphasized that our study examined cannabis’ impact on previously
demonstrated markers of treatment response and does not provide conclusions about whether
cannabis impacts treatment outcomes. Indeed, our sample did not demonstrate any meaningful
differences between cannabis users and non-users in overall positive and negative psychotic
symptoms, nor in the cognitive symptoms associated with SSD. This is consistent with previous
neuroimaging studies that have demonstrated that both acute and chronic cannabis exposure can
disrupt activity of brain networks involved in cognitive processes without impacting behavioral
performance (Bossong et al., 2012; Jager et al., 2007; Jager et al., 2010). It may be that cannabis
has a subtle effect on neural connectivity that does not translate to noticeable behavioral
differences in psychotic symptomology or treatment outcomes. Such differences in neural
connectivity may still be critical to consider in the development of neuroimaging biomarkers.
In conclusion, our findings highlight that while cannabis may not directly impact
biomarkers, there may be differences in the relationship between recent cannabis use and the SCI
that impacts treatment response. Future research with a larger sample size of patients with
longitudinal data will be necessary to robustly detect subtle effects of cannabis’ impact on the
predictive utility of biomarkers. In efforts towards biomarker development, it will be crucial to
account for the confounding effect of nicotine, as well as differences in cannabis composition
and patterns of use.
As the development of biomarkers to predict treatment response becomes an increasingly
significant goal of the medical community, it is critical that investigators consider the influence
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of cannabis and other substances on their predictors of interest, thereby ensuring that biomarkers
are generalizable to the significant proportion of patients currently using cannabis.

56

Impact of Cannabis on Biomarkers of AP Treatment
References
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., … Laruelle,
M. (2000). Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.
Proceedings of the National Academy of Sciences of the United States of America, 97(14),
8104–9. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10884434
Acquas, E., Pisanu, A., Marrocu, P., Goldberg, S. R., & Di Chiara, G. (2001). Δ9tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a
microdialysis study. European journal of pharmacology, 419(2-3), 155-161.
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental
disorders: DSM-5. American Psychiatric Association. Retrieved from
https://www.appi.org/Course/Book/Subscription/JournalSubscription/id3322/Diagnostic_and_Statistical_Manual_of_Mental_Disorders_%28DSM-5®%29
Anticevic, A., Hu, X., Xiao, Y., Hu, J., Li, F., Bi, F., … Gong, Q. (2015). Early-Course
Unmedicated Schizophrenia Patients Exhibit Elevated Prefrontal Connectivity Associated
with Longitudinal Change. Journal of Neuroscience, 35(1), 267–286.
https://doi.org/10.1523/JNEUROSCI.2310-14.2015
Arendash, G. W., Sengstock, G. J., Sanberg, P. R., & Kem, W. R. (1995). Improved learning and
memory in aged rats with chronic administration of the nicotinic receptor agonist GTS21. Brain research, 674(2), 252-259.
Argyelan, M., Gallego, J. A., Robinson, D. G., Ikuta, T., Sarpal, D., John, M., … Szeszko, P. R.
(2015). Abnormal Resting State fMRI Activity Predicts Processing Speed Deficits in FirstEpisode Psychosis. Neuropsychopharmacology, 40(7), 1631–1639.
https://doi.org/10.1038/npp.2015.7

57

Impact of Cannabis on Biomarkers of AP Treatment
Argyelan, M., Ikuta, T., DeRosse, P., Braga, R. J., Burdick, K. E., John, M., … Szeszko, P. R.
(2014). Resting-State fMRI Connectivity Impairment in Schizophrenia and Bipolar
Disorder. Schizophrenia Bulletin, 40(1), 100–110. https://doi.org/10.1093/schbul/sbt092
Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002).
Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.
Bmj, 325(7374), 1212-1213.
Asbridge, M., Duff, C., Marsh, D. C., & Erickson, P. G. (2014). Problems with the identification
of ‘problematic'cannabis use: Examining the issues of frequency, quantity, and drug use
environment. European addiction research, 20(5), 254-267.
Aukes, M. F., Alizadeh, B. Z., Sitskoorn, M. M., Kemner, C., Ophoff, R. A., & Kahn, R. S.
(2009). Genetic overlap among intelligence and other candidate endophenotypes for
schizophrenia. Biological psychiatry, 65(6), 527-534.
Azofeifa, A., Mattson, M. E., Schauer, G., McAfee, T., Grant, A., & Lyerla, R. (2016). National
Estimates of Marijuana Use and Related Indicators — National Survey on Drug Use and
Health, United States, 2002–2014. MMWR. Surveillance Summaries, 65(11), 1–28.
https://doi.org/10.15585/mmwr.ss6511a1
Barrett, S. P., Darredeau, C., & Pihl, R. O. (2006). Patterns of simultaneous polysubstance use in
drug using university students. Human Psychopharmacology: Clinical and
Experimental, 21(4), 255-263.
Batalla, A., Bhattacharyya, S., Yücel, M., Fusar-Poli, P., Crippa, J. A., Nogué, S., … MartinSantos, R. (2013). Structural and Functional Imaging Studies in Chronic Cannabis Users: A
Systematic Review of Adolescent and Adult Findings. PLoS ONE, 8(2).
https://doi.org/10.1371/journal.pone.0055821

58

Impact of Cannabis on Biomarkers of AP Treatment
Battistella, G., Fornari, E., Annoni, J.-M., Chtioui, H., Dao, K., Fabritius, M., … Giroud, C.
(2014). Long-term effects of cannabis on brain structure. Neuropsychopharmacology, 39(9),
2041–8. https://doi.org/10.1038/npp.2014.67
Benes, F.M., Vincent, S.L., Marie, A., Kahn, Y. (1996). Up-regulation of GABAA receptor
binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience, 75,
1021–1031.
Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., WintonBrown, T., ... & Mehta, M. A. (2010). Opposite effects of Δ-9-tetrahydrocannabinol and
cannabidiol on human brain function and psychopathology. Neuropsychopharmacology,
35(3), 764-774.
Bhattacharyya, S., Falkenberg, I., Martin-Santos, R., Atakan, Z., Crippa, J. A., Giampietro, V.,
… McGuire, P. (2015). Cannabinoid modulation of functional connectivity within regions
processing attentional salience. Neuropsychopharmacology : Official Publication of the
American College of Neuropsychopharmacology, 40(6), 1343–52.
https://doi.org/10.1038/npp.2014.258
Biala, G., & Kruk, M. (2008). Cannabinoid receptor ligands suppress memory-related effects of
nicotine in the elevated plus maze test in mice. Behavioural brain research, 192(2), 198202.
Bilder, R. M., Goldman, R. S., Robinson, D., Reiter, G., Bell, L., Bates, J. A., ... & Geisler, S.
(2000). Neuropsychology of first-episode schizophrenia: initial characterization and clinical
correlates. American Journal of Psychiatry, 157(4), 549-559.
Birn, R. M., Molloy, E. K., Patriat, R., Parker, T., Meier, T. B., Kirk, G. R., … Prabhakaran, V.
(2013). The effect of scan length on the reliability of resting-state fMRI connectivity

59

Impact of Cannabis on Biomarkers of AP Treatment
estimates. NeuroImage, 83, 550–8. https://doi.org/10.1016/j.neuroimage.2013.05.099
Blair Thies, M., DeRosse, P., Sarpal, D. K., Argyelan, M., Fales, C. L., Gallego, J. A., ... &
Malhotra, A. K. (2020). Interaction of Cannabis Use Disorder and Striatal Connectivity in
Antipsychotic Treatment Response. Schizophrenia Bulletin Open, 1(1), sgaa014.
Blanco-Hinojo, L., Pujol, J., Harrison, B. J., Macià, D., Batalla, A., Nogué, S., … Martín-Santos,
R. (2017). Attenuated frontal and sensory inputs to the basal ganglia in cannabis users.
Addiction Biology, 22(4), 1036–1047. https://doi.org/10.1111/adb.12370
Bossong, M. G., van Berckel, B. N., Boellaard, R., Zuurman, L., Schuit, R. C., Windhorst, A. D.,
… Kahn, R. S. (2009). Δ9-Tetrahydrocannabinol Induces Dopamine Release in the Human
Striatum. Neuropsychopharmacology, 34(3), 759–766.
https://doi.org/10.1038/npp.2008.138
Bossong, M. G., Jager, G., van Hell, H. H., Zuurman, L., Jansma, J. M., Mehta, M. A., ... &
Ramsey, N. F. (2012). Effects of Δ9-tetrahydrocannabinol administration on human
encoding and recall memory function: a pharmacological fMRI study. Journal of Cognitive
Neuroscience, 24(3), 588-599.
Bossong, M. G., Mehta, M. A., van Berckel, B. N. M., Howes, O. D., Kahn, R. S., & Stokes, P.
R. A. (2015). Further human evidence for striatal dopamine release induced by
administration of ∆9-tetrahydrocannabinol (THC): selectivity to limbic striatum.
Psychopharmacology, 232(15), 2723–9. https://doi.org/10.1007/s00213-015-3915-0
Breitborde, N. J., Srihari, V. H., & Woods, S. W. (2009). Review of the operational definition for
first-episode psychosis. Early intervention in psychiatry, 3(4), 259–265.
https://doi.org/10.1111/j.1751-7893.2009.00148.x
Brightfield Group (2018). Hemp CBD Report.

60

Impact of Cannabis on Biomarkers of AP Treatment
Brisch, R., Saniotis, A., Wolf, R., Bielau, H., Bernstein, H.-G., Steiner, J., … Jablensky, A. V.
(2014). The role of dopamine in schizophrenia from a neurobiological and evolutionary
perspective: old fashioned, but still in vogue. https://doi.org/10.3389/fpsyt.2014.00047
Brzozowska, N. I., de Tonnerre, E. J., Li, K. M., Wang, X. S., Boucher, A. A., Callaghan, P. D.,
… Arnold, J. C. (2017). The Differential Binding of Antipsychotic Drugs to the ABC
Transporter P-Glycoprotein Predicts Cannabinoid–Antipsychotic Drug Interactions.
Neuropsychopharmacology, 42(11), 2222–2231. https://doi.org/10.1038/npp.2017.50
Buckley, P. F., Miller, B. J., Lehrer, D. S., & Castle, D. J. (2009). Psychiatric Comorbidities and
Schizophrenia. Schizophrenia Bulletin, 35(2), 383–402.
https://doi.org/10.1093/schbul/sbn135
Bugra, H., Studerus, E., Rapp, C., Tamagni, C., Aston, J., Borgwardt, S., & Riecher-Rössler, A.
(2013). Cannabis use and cognitive functions in at-risk mental state and first episode
psychosis. Psychopharmacology, 230(2), 299-308.
Burger, G. K., Calsyn, R. J., Morse, G. A., Klinkenberg, W. D., & Trusty, M. L. (1997). Factor
structure of the expanded Brief Psychiatric Rating Scale. Journal of clinical
psychology, 53(5), 451–454. https://doi.org/10.1002/(sici)10974679(199708)53:5<451::aid-jclp5>3.0.co;2-q
Burns, J. K. (2012). Cannabis use and duration of untreated psychosis: a systematic review and
meta-analysis. Current Pharmaceutical Design, 18(32), 5093–104. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/22716138
Cascini, F., Aiello, C., & Di Tanna, G. (2012). Increasing delta-9-tetrahydrocannabinol (Δ-9THC) content in herbal cannabis over time: systematic review and meta-analysis. Current
drug abuse reviews, 5(1), 32-40.

61

Impact of Cannabis on Biomarkers of AP Treatment
Cao, B., Cho, R. Y., Chen, D., Xiu, M., Wang, L., Soares, J. C., & Zhang, X. Y. (2018).
Treatment response prediction and individualized identification of first-episode drug-naïve
schizophrenia using brain functional connectivity. Molecular psychiatry, 1-8.
Carey, K. B., Carey, M. P., Maisto, S. A., & Henson, J. M. (2004). Temporal stability of the
timeline followback interview for alcohol and drug use with psychiatric outpatients. Journal
of Studies on Alcohol, 65(6), 774–81. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/15700516
Centers for Disease Control and Prevention (CDC), Brener, N. D., Kann, L., Shanklin, S.,
Kinchen, S., Eaton, D. K., … Centers for Disease Control and Prevention (CDC). (2013).
Methodology of the Youth Risk Behavior Surveillance System--2013. MMWR.
Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations
and Reports, 62(RR-1), 1–20. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/23446553
Cirillo, M. A., & Seidman, L. J. (2003). Verbal declarative memory dysfunction in
schizophrenia: from clinical assessment to genetics and brain mechanisms.
Neuropsychology Review, 13(2), 43-77.
Clarke, H. F., Dalley, J. W., Crofts, H. S., Robbins, T. W., & Roberts, A. C. (2004). Cognitive
inflexibility after prefrontal serotonin depletion. Science, 304(5672), 878-880.
Cohen, J. (1988). Statistical power analysis for the behavioral sciences. L. Erlbaum Associates.
Cohen, M., Rasser, P. E., Peck, G., Carr, V. J., Ward, P. B., Thompson, P. M., … Schall, U.
(2012). Cerebellar grey-matter deficits, cannabis use and first-episode schizophrenia in
adolescents and young adults. The International Journal of Neuropsychopharmacology /
Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum

62

Impact of Cannabis on Biomarkers of AP Treatment
(CINP), 15(3), 297–307. https://doi.org/10.1017/S146114571100068X
Conley, R. R., & Kelly, D. L. (2001). Management of treatment resistance in schizophrenia.
Biological Psychiatry, 50(11), 898-911.
Cornblatt, B., Obuchowski, M., Roberts, S., Pollack, S., & Erlenmeyer–Kimling, L. (1999).
Cognitive and behavioral precursors of schizophrenia. Development and
psychopathology, 11(3), 487-508.
Correll, C. U., Malhotra, A. K., Kaushik, S., McMeniman, M., & Kane, J. M. (2003). Early
Prediction of Antipsychotic Response in Schizophrenia. American Journal of Psychiatry,
160(11), 2063–2065. https://doi.org/10.1176/appi.ajp.160.11.2063
Coulston, C. M., Perdices, M., & Tennant, C. C. (2007). The neuropsychology of cannabis and
other substance use in schizophrenia: review of the literature and critical evaluation of
methodological issues. Australian & New Zealand Journal of Psychiatry, 41(11), 869-884.
Coyle, J. T. (2004). The GABA-glutamate connection in schizophrenia: which is the proximate
cause?. Biochemical pharmacology, 68(8), 1507-1514.
Creese, I., Burt, D. R., & Snyder, S. H. (1976). Dopamine receptor binding predicts clinical and
pharmacological potencies of antischizophrenic drugs. Science, 192 (4238), 481-483.
Curran, V. H., Brignell, C., Fletcher, S., Middleton, P., & Henry, J. (2002). Cognitive and
subjective dose-response effects of acute oral Δ 9-tetrahydrocannabinol (THC) in infrequent
cannabis users. Psychopharmacology, 164(1), 61-70.
D’Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G.,
… Krystal, J. H. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia:
Implications for cognition, psychosis, and addiction. Biological Psychiatry, 57(6), 594–608.
https://doi.org/10.1016/J.BIOPSYCH.2004.12.006

63

Impact of Cannabis on Biomarkers of AP Treatment
Dalack, G. W., Healy, D. J., & Meador-Woodruff, J. H. (1998). Nicotine dependence in
schizophrenia: clinical phenomena and laboratory findings. American Journal of
Psychiatry, 155(11), 1490-1501.
Dalley, J., Theobald, D., Pereira, E., Li, P. M. M. C., & Robbins, T. (2002). Specific
abnormalities in serotonin release in the prefrontal cortex of isolation-reared rats measured
during behavioural performance of a task assessing visuospatial attention and
impulsivity. Psychopharmacology, 164(3), 329-340.
da Silva Alves, F., Figee, M., van Amelsvoort, T., Veltman, D., & de Haan, L. (2008). The
revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies
with atypical antipsychotic medication. Psychopharmacology Bulletin, 41(1), 121–32.
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/18362875
Davis K.L, Kahn, R.S., Ko, G., Davidson, M. (1991). Dopamine in schizophrenia: a review and
reconceptualization. American Journal of Psychiatry, 148, 1474-1486.
De Leon, J., & Diaz, F. J. (2005). A meta-analysis of worldwide studies demonstrates an
association between schizophrenia and tobacco smoking behaviors. Schizophrenia
research, 76(2-3), 135-157.
DeMarce, J. M., Burden, J. L., Lash, S. J., Stephens, R. S., & Grambow, S. C. (2007).
Convergent validity of the Timeline Followback for persons with comorbid psychiatric
disorders engaged in residential substance use treatment. Addictive Behaviors, 32(8), 1582–
1592. https://doi.org/10.1016/J.ADDBEH.2006.11.015
Desai, P. R., Lawson, K. A., Barner, J. C., & Rascati, K. L. (2013). Estimating the direct and
indirect costs for community‐dwelling patients with schizophrenia. Journal of
Pharmaceutical Health Services Research, 4(4), 187-194.

64

Impact of Cannabis on Biomarkers of AP Treatment
Dickson, H., Laurens, K. R., Cullen, A. E., & Hodgins, S. (2012). Meta-analyses of cognitive
and motor function in youth aged 16 years and younger who subsequently develop
schizophrenia. Psychological medicine, 42(4), 743-755.
Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., … Murray, R.
M. (2009). High-potency cannabis and the risk of psychosis. British Journal of Psychiatry,
195(6), 488–491. https://doi.org/10.1192/bjp.bp.109.064220
Di Martino, A., Scheres, A., Margulies, D. S., Kelly, A. M. C., Uddin, L. Q., Shehzad, Z., …
Milham, M. P. (2008). Functional Connectivity of Human Striatum: A Resting State fMRI
Study. Cerebral Cortex, 18(12), 2735–2747. https://doi.org/10.1093/cercor/bhn041
D’Souza, D., Abi-Saab, W.M., Madonic, S., Forselius-Bielen, K., Doersch, A., Braley, G.,
Gueorguieva, R., Cooper, T.B., Harrison-Krystal, J. (2005). Delta-9-Tetrahydrocannabinol
Effects in Schizophrenia: Implications for Cognition, Psychosis and Addiction. Biological
Psychiatry, 57, 594-608.
Durany, N., Zöchling, R., Boissl, K. W., Paulus, W., Ransmayr, G., Tatschner, T., ... & Riederer,
P. (2000). Human post-mortem striatal α4β2 nicotinic acetylcholine receptor density in
schizophrenia and Parkinson's syndrome. Neuroscience Letters, 287(2), 109-112.
Englund, A., Morrison, P. D., Nottage, J., Hague, D., Kane, F., Bonaccorso, S., ... & Feilding, A.
(2013). Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent
memory impairment. Journal of psychopharmacology, 27(1), 19-27.
Fatouros-Bergman, H., Cervenka, S., Flyckt, L., Edman, G., & Farde, L. (2014). Meta-analysis
of cognitive performance in drug-naïve patients with schizophrenia. Schizophrenia
research, 158(1-3), 156-162.
Ferraro, L., Tomasini, M. C., Gessa, G. L., Bebe, B. W., Tanganelli, S., & Antonelli, T. (2001).

65

Impact of Cannabis on Biomarkers of AP Treatment
The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat
cerebral cortex: an in vivo and in vitro study. Cerebral Cortex, 11(8), 728-733.
First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. W. (1997). Structured clinical
interview for DSM-IV-TR Axis I Disorders, Research Version, Patients Edition. (SCID-I/P).
New York: Biometrics Research, New York State Psychiatric Institute.
Fischer, A. S., Whitfield-Gabrieli, S., Roth, R. M., Brunette, M. F., & Green, A. I. (2014).
Impaired functional connectivity of brain reward circuitry in patients with schizophrenia
and cannabis use disorder: Effects of cannabis and THC. Schizophrenia Research, 158(1–
3), 176–182. https://doi.org/10.1016/j.schres.2014.04.033
Fowler, I. L., Carr, V. J., Carter, N. T., & Lewin, T. J. (1998). Patterns of current and lifetime
substance use in schizophrenia. Schizophrenia bulletin, 24(3), 443-455.
Freedman, R., Adams, C. E., & Leonard, S. (2000). The α7-nicotinic acetylcholine receptor and
the pathology of hippocampal interneurons in schizophrenia. Journal of chemical
neuroanatomy, 20(3-4), 299-306.
Friedman, J. I., Temporini, H., & Davis, K. L. (1999). Pharmacologic strategies for augmenting
cognitive performance in schizophrenia. Biological psychiatry, 45(1), 1-16.
Friston, K. J. (1998). The disconnection hypothesis. Schizophrenia research, 30(2), 115-125.
Fusar-Poli, P., Howes, O. D., Allen, P., Broome, M., Valli, I., Asselin, M. C., ... & McGuire, P.
(2011). Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine
dysfunction in people at clinical high risk for psychosis. Molecular psychiatry, 16(1), 67.
Gallego, J. A., Robinson, D. G., Sevy, S. M., Napolitano, B., McCormack, J., Lesser, M. L., &
Kane, J. M. (2011). Time to treatment response in first-episode schizophrenia: should acute
treatment trials last several months? The Journal of Clinical Psychiatry, 72(12), 1691–6.

66

Impact of Cannabis on Biomarkers of AP Treatment
https://doi.org/10.4088/JCP.10m06349
Goldman-Rakic, P. S. (1994). Working memory dysfunction in schizophrenia. The Frontal
Lobes and Neuropsychiatric Illness. Washington, DC, 71-82.
Goldstein, R. Z., Giovannetti, T., Schullery, M., Zuffante, P. A., Lieberman, J. A., Robinson, D.
G., … Bilder, R. M. (2002). Neurocognitive correlates of response to treatment in formal
thought disorder in patients with first-episode schizophrenia. Neuropsychiatry,
Neuropsychology, and Behavioral Neurology, 15(2), 88–98. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/12050471
Gonzalez-Castillo, J., Handwerker, D. A., Robinson, M. E., Hoy, C. W., Buchanan, L. C., Saad,
Z. S., & Bandettini, P. A. (2014). The spatial structure of resting state connectivity stability
on the scale of minutes. Frontiers in Neuroscience, 8, 138.
https://doi.org/10.3389/fnins.2014.00138
Grace, A. A. (2016). Dysregulation of the dopamine system in the pathophysiology of
schizophrenia and depression. Nature Reviews. Neuroscience, 17(8), 524–32.
https://doi.org/10.1038/nrn.2016.57
Haber, S. N. (2011). Neuroanatomy of Reward: A View from the Ventral Striatum. In J.
Gottfried (Ed.), Neurobiology of Sensation and Reward. Boca Raton, FL: CRC Press/Taylor
& Francis. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22593898
Hadley, J. A., Nenert, R., Kraguljac, N. V., Bolding, M. S., White, D. M., Skidmore, F. M., ... &
Lahti, A. C. (2014). Ventral tegmental area/midbrain functional connectivity and response
to antipsychotic medication in schizophrenia. Neuropsychopharmacology, 39(4), 10201030.
Hasin, D. S., Kerridge, B. T., Saha, T. D., Huang, B., Pickering, R., Smith, S. M., … Grant, B. F.

67

Impact of Cannabis on Biomarkers of AP Treatment
(2016). Prevalence and Correlates of DSM-5 Cannabis Use Disorder, 2012–2013: Findings
from the National Epidemiologic Survey on Alcohol and Related Conditions – III. The
American Journal of Psychiatry, 173(6), 588.
https://doi.org/10.1176/APPI.AJP.2015.15070907
Hedden, S. L., Kennet, J., Lipari, R., Medley, G., & Tice, P. (2015). Behavioral Health Trends in
the United States: Results from the 2014 National Survey on Drug Use and Health (HHS
Publication No. SMA 15-4927, NSDUH Series H-50). Retrieved from
http://www.samhsa.gov/data
Henquet, C., van Os, J., Kuepper, R., Delespaul, P., Smits, M., Campo, J. a., & Myin-Germeys,
I. (2010). Psychosis reactivity to cannabis use in daily life: an experience sampling study.
The British Journal of Psychiatry, 196(6), 447–453.
https://doi.org/10.1192/bjp.bp.109.072249
Hides, L., Dawe, S., Kavanagh, D. J., & Young, R. M. (2006). Psychotic symptom and cannabis
relapse in recent-onset psychosis. The British Journal of Psychiatry, 189(2). Retrieved from
http://bjp.rcpsych.org/content/189/2/137
Honey, G. D., Suckling, J., Zelaya, F., Long, C., Routledge, C., Jackson, S., … Bullmore, E. T.
(2003). Dopaminergic drug effects on physiological connectivity in a human cortico-striatothalamic system. Brain, 126(8), 1767–81. https://doi.org/10.1093/brain/awg184
Howes, O. D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., & Kapur, S.
(2012). The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for
Treatment. Archives of General Psychiatry, 69(8), 776–86.
https://doi.org/10.1001/archgenpsychiatry.2012.169
Howes, O. D., & Kapur, S. (2014). A neurobiological hypothesis for the classification of

68

Impact of Cannabis on Biomarkers of AP Treatment
schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic). The British
Journal of Psychiatry , 205, 1–3. https://doi.org/10.1192/bjp.bp.113.138578
Howes, O. D., & Nour, M. M. (2016). Dopamine and the aberrant salience hypothesis of
schizophrenia. World Psychiatry : Official Journal of the World Psychiatric Association
(WPA), 15(1), 3–4. https://doi.org/10.1002/wps.20276
Hughes, J.R., Hatsukami, D.K., Mitchell, J. E., & Dahlgren, L. A. (1986). Prevalence of smoking
among psychiatric outpatients. Am J psychiatry, 143(8), 993-997.
Jacobsen, L. K., Pugh, K. R., Constable, R. T., Westerveld, M., & Mencl, W. E. (2007).
Functional correlates of verbal memory deficits emerging during nicotine withdrawal in
abstinent adolescent cannabis users. Biological psychiatry, 61(1), 31-40.
Jager, G., Block, R. I., Luijten, M., & Ramsey, N. F. (2010). Cannabis use and memory brain
function in adolescent boys: a cross-sectional multicenter functional magnetic resonance
imaging study. Journal of the American Academy of Child & Adolescent Psychiatry, 49(6),
561-572.
Jager, G., Van Hell, H. H., De Win, M. M., Kahn, R. S., Van Den Brink, W., Van Ree, J. M., &
Ramsey, N. F. (2007). Effects of frequent cannabis use on hippocampal activity during an
associative memory task. European Neuropsychopharmacology, 17(4), 289-297.
James, A., Hough, M., James, S., Winmill, L., Burge, L., Nijhawan, S., … Zarei, M. (2011).
Greater white and grey matter changes associated with early cannabis use in adolescentonset schizophrenia (AOS). Schizophrenia Research, 128(1–3), 91–97.
https://doi.org/10.1016/j.schres.2011.02.014
Jensen, J., & Kapur, S. (2009). Salience and psychosis: moving from theory to practise.
Psychological Medicine, 39(2), 197. https://doi.org/10.1017/S0033291708003899

69

Impact of Cannabis on Biomarkers of AP Treatment
Jentsch, J. D., Andrusiak, E., Tran, A., Bowers Jr, M. B., & Roth, R. H. (1997). Δ9Tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and
impairs spatial working memory in the rat: blockade of dopaminergic effects with
HA966. Neuropsychopharmacology, 16(6), 426-432.
Jockers-Scherübl, M. C., Wolf, T., Radzei, N., Schlattmann, P., Rentzsch, J., de Castro, A. G. C.,
& Kühl, K. P. (2007). Cannabis induces different cognitive changes in schizophrenic
patients and in healthy controls. Progress in Neuro-Psychopharmacology and Biological
Psychiatry, 31(5), 1054-1063.
Juckel, G., Schlagenhauf, F., Koslowski, M., Wüstenberg, T., Villringer, A., Knutson, B., …
Heinz, A. (2006). Dysfunction of ventral striatal reward prediction in schizophrenia.
NeuroImage, 29(2), 409–416. https://doi.org/10.1016/j.neuroimage.2005.07.051
Kahn, R. S., & Keefe, R. S. (2013). Schizophrenia is a cognitive illness: time for a change in
focus. JAMA psychiatry, 70(10), 1107-1112.
Keefe, R., Goldberg, T., Harvey, P., Gold, J. M., Poe, M., & Coughenour, L. (2004). The brief
assessment of cognition in schizophrenia: Reliability, sensitivity, and comparsion with a
standard neurocognitive battery. Schizophrenia Research, 68, 238–297.
Kelly, C., de Zubicaray, G., Di Martino, A., Copland, D. A., Reiss, P. T., Klein, D. F., …
McMahon, K. (2009). L-Dopa Modulates Functional Connectivity in Striatal Cognitive and
Motor Networks: A Double-Blind Placebo-Controlled Study. Journal of Neuroscience,
29(22), 7364–7378. https://doi.org/10.1523/JNEUROSCI.0810-09.2009
Kessler, R. C., Birnbaum, H., Demler, O., Falloon, I. R., Gagnon, E., Guyer, M., ... & Wu, E. Q.
(2005). The prevalence and correlates of nonaffective psychosis in the National
Comorbidity Survey Replication (NCS-R). Biological psychiatry, 58(8), 668-676.

70

Impact of Cannabis on Biomarkers of AP Treatment
Khandaker, G. M., Barnett, J. H., White, I. R., & Jones, P. B. (2011). A quantitative metaanalysis of population-based studies of premorbid intelligence and
schizophrenia. Schizophrenia research, 132(2-3), 220-227.
Koskinen, J., Löhönen, J., Koponen, H., Isohanni, M., & Miettunen, J. (2010). Rate of cannabis
use disorders in clinical samples of patients with schizophrenia: A meta-analysis.
Schizophrenia Bulletin, 36(6), 1115–1130. https://doi.org/10.1093/schbul/sbp031
Kuepper, R., Morrison, P. D., van Os, J., Murray, R. M., Kenis, G., & Henquet, C. (2010). Does
dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of
findings across disciplines. Schizophrenia Research, 121(1–3), 107–117.
https://doi.org/10.1016/j.schres.2010.05.031
Lahti, A. C., Weiler, M. A., Holcomb, H. H., Tamminga, C. A., & Cropsey, K. L. (2009).
Modulation of Limbic Circuitry Predicts Treatment Response to Antipsychotic Medication:
A Functional Imaging Study in Schizophrenia. Neuropsychopharmacology, 34(13), 2675–
2690. https://doi.org/10.1038/npp.2009.94
Leeson, V. C., Harrison, I., Ron, M. A., Barnes, T. R., & Joyce, E. M. (2011). The effect of
cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode
schizophrenia. Schizophrenia bulletin, 38(4), 873-880.
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., ... & Kissling, W.
(2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a
multiple-treatments meta-analysis. The Lancet, 382(9896), 951-962.
Levin, E. D., & Christopher, N. C. (2002). Persistence of nicotinic agonist RJR 2403‐induced
working memory improvement in rats. Drug development research, 55(2), 97-103.
Levin, E. D., & Rezvani, A. H. (2007). Nicotinic interactions with antipsychotic drugs, models

71

Impact of Cannabis on Biomarkers of AP Treatment
of schizophrenia and impacts on cognitive function. Biochemical pharmacology, 74(8),
1182-1191.
Li, A., Zalesky, A., Yue, W., Howes, O., Yan, H., Liu, Y., ... & Li, J. (2020). A neuroimaging
biomarker for striatal dysfunction in schizophrenia. Nature Medicine, 1-8.
Liang, M., Zhou, Y., Jiang, T., Liu, Z., Tian, L., Liu, H., & Hao, Y. (2006). Widespread
functional disconnectivity in schizophrenia with resting-state functional magnetic resonance
imaging. Neuroreport, 17(2), 209-213.
Liddle, P. F., Friston, K. J., Frith, C. D., Hirsch, S. R., Jones, T., & Frackowiak, R. S. (1992).
Patterns of cerebral blood flow in schizophrenia. British Journal of Psychiatry, 160, 179–
86. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1540757
Løberg, E. M., & Hugdahl, K. (2009). Cannabis use and cognition in schizophrenia. Frontiers in
Human Neuroscience, 3, 53.
Lum, G., & Mushlin, B. (2004). Urine Drug Testing: Approaches to Screening and Confirmation
Testing. Laboratory Medicine, 35(6), 368–373.
https://doi.org/10.1309/QHJCKA4235EGPEGF
Madras, B. K. (2013). History of the Discovery of the Antipsychotic Dopamine D2 Receptor: A
Basis for the Dopamine Hypothesis of Schizophrenia. Journal of the History of the
Neurosciences, 22(1), 62–78. https://doi.org/10.1080/0964704X.2012.678199
Malchow, B., Hasan, A., Fusar-Poli, P., Schmitt, A., Falkai, P., & Wobrock, T. (2013). Cannabis
abuse and brain morphology in schizophrenia: A review of the available evidence.
European Archives of Psychiatry and Clinical Neuroscience, 263(1), 3–13.
https://doi.org/10.1007/s00406-012-0346-3
Martin-Santos, R., Fagundo, A. B., Crippa, J. A., Atakan, Z., Bhattacharyya, S., Allen, P., …

72

Impact of Cannabis on Biomarkers of AP Treatment
McGuire, P. (2010). Neuroimaging in cannabis use: a systematic review of the literature.
Psychol Med, 40(3), 383–398. https://doi.org/S0033291709990729
[pii]\r10.1017/S0033291709990729
McGowan, S., Lawrence, A. D., Sales, T., Quested, D., & Grasby, P. (2004). Presynaptic
Dopaminergic Dysfunction in Schizophrenia. Archives of General Psychiatry, 61(2), 134.
https://doi.org/10.1001/archpsyc.61.2.134
McGuire, P. K., & Frith, C. D. (1996). Disordered functional connectivity in schizophrenia.
Psychological medicine, 26(4), 663-667.
Meier, M. H., Caspi, A., Ambler, A., Harrington, H., Houts, R., Keefe, R. S., ... & Moffitt, T. E.
(2012). Persistent cannabis users show neuropsychological decline from childhood to
midlife. Proceedings of the National Academy of Sciences, 109(40), E2657-E2664.
Mejia, A. F., Nebel, M. B., Barber, A. D., Choe, A. S., & Lindquist, M. A. (2016). Effects of
Scan Length and Shrinkage on Reliability of Resting-State Functional Connectivity in the
Human Connectome Project. Retrieved from https://arxiv.org/pdf/1606.06284.pdf
Mesholam-Gately, R. I., Giuliano, A. J., Goff, K. P., Faraone, S. V., & Seidman, L. J. (2009).
Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology,
23(3), 315.
Meyer-Lindenberg, A., Miletich, R. S., Kohn, P. D., Esposito, G., Carson, R. E., Quarantelli, M.,
... & Berman, K. F. (2002). Reduced prefrontal activity predicts exaggerated striatal
dopaminergic function in schizophrenia. Nature neuroscience, 5(3), 267.
Mollon, J., & Reichenberg, A. (2018). Cognitive development prior to onset of
psychosis. Psychological medicine, 48(3), 392-403.
Morgan, C. J., Schafer, G., Freeman, T. P., & Curran, H. V. (2010). Impact of cannabidiol on the

73

Impact of Cannabis on Biomarkers of AP Treatment
acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. The
British Journal of Psychiatry, 197(4), 285-290.
Morgan, C. J. A., Gardener, C., Schafer, G., Swan, S., Demarchi, C., Freeman, T. P., ... &
Wingham, G. (2012). Sub-chronic impact of cannabinoids in street cannabis on cognition,
psychotic-like symptoms and psychological well-being. Psychological medicine, 42(2),
391-400.
Müller-Vahl, K. R., & Emrich, H. M. (2008). Cannabis and schizophrenia: towards a
cannabinoid hypothesis of schizophrenia. Expert Review of Neurotherapeutics, 8(7), 10371048.
Mumford, J. A. (2012). A power calculation guide for fMRI studies. Social Cognitive and
Affective Neuroscience, 7(6), 738–742. https://doi.org/10.1093/scan/nss059
NIDA. (2020). Tobacco/Nicotine and Vaping. Retrieved from https://www.drugabuse.gov/drugsabuse/tobacconicotine-vaping on 2020, March 25.
Nielsen, M. Ø., Rostrup, E., Wulff, S., Bak, N., Lublin, H., Kapur, S., & Glenthøj, B. (2012).
Alterations of the Brain Reward System in Antipsychotic Naïve Schizophrenia Patients.
Biological Psychiatry, 71(10), 898–905. https://doi.org/10.1016/j.biopsych.2012.02.007
Núñez, C., Ochoa, S., Huerta-Ramos, E., Baños, I., Barajas, A., Dolz, M., ... & GENIPE Group.
(2016). Cannabis use and cognitive function in first episode psychosis: differential effect of
heavy use. Psychopharmacology, 233(5), 809-821.
Oleson, E. B., & Cheer, J. F. (2012). A brain on cannabinoids: The role of dopamine release in
reward seeking. Cold Spring Harbor Perspectives in Medicine, 2(8), 1–13.
https://doi.org/10.1101/cshperspect.a012229
Patel, R., Wilson, R., Jackson, R., Ball, M., Shetty, H., Broadbent, M., … Bhattacharyya, S.

74

Impact of Cannabis on Biomarkers of AP Treatment
(2016). Association of cannabis use with hospital admission and antipsychotic treatment
failure in first episode psychosis: an observational study. BMJ Open, 6(3), e009888.
https://doi.org/10.1136/bmjopen-2015-009888
Pogarell, O., Koch, W., Karch, S., Dehning, S., Müller, N., Tatsch, K., … Möller, H.-J. (2012).
Dopaminergic Neurotransmission in Patients with Schizophrenia in Relation to Positive and
Negative Symptoms. Pharmacopsychiatry, 45(S 01), S36–S41. https://doi.org/10.1055/s0032-1306313
Pope, H. G., Gruber, A. J., Hudson, J. I., Huestis, M. A., & Yurgelun-Todd, D. (2001).
Neuropsychological performance in long-term cannabis users. Archives of general
psychiatry, 58(10), 909-915.
Potvin, S., Joyal, C. C., Pelletier, J., & Stip, E. (2008). Contradictory cognitive capacities among
substance-abusing patients with schizophrenia: a meta-analysis. Schizophrenia
Research, 100(1-3), 242-251.
Power, J. D., Barnes, K. A., Snyder, A. Z., Schlaggar, B. L., & Petersen, S. E. (2012). Spurious
but systematic correlations in functional connectivity MRI networks arise from subject
motion. NeuroImage, 59(3), 2142–2154. https://doi.org/10.1016/j.neuroimage.2011.10.018
Power, J. D., Schlaggar, B. L., & Petersen, S. E. (2015). Recent progress and outstanding issues
in motion correction in resting state fMRI. NeuroImage, 105, 536–551.
https://doi.org/10.1016/j.neuroimage.2014.10.044
Rabin, R. A., & George, T. P. (2015). A review of co‐morbid tobacco and cannabis use
disorders: Possible mechanisms to explain high rates of co‐use. The American journal on
addictions, 24(2), 105-116.
Rabiner, C. J., Wegner, J. T., & Kane, J. M. (1986). Outcome study of first-episode psychosis. I:

75

Impact of Cannabis on Biomarkers of AP Treatment
Relapse rates after 1 year. American Journal of Psychiatry, 143(9), 1155–1158.
https://doi.org/10.1176/ajp.143.9.1155
Rais, M., Cahn, W., Van Haren, N., Schnack, H., Caspers, E., Pol, H. H., & Kahn, R. (2008).
Excessive brain volume loss over time in cannabis-using first-episode schizophrenia
patients. American Journal of Psychiatry, 165(4), 490–496.
https://doi.org/10.1176/appi.ajp.2007.07071110
Ramaekers, J. G., Evers, E. A., Theunissen, E. L., Kuypers, K. P. C., Goulas, A., & Stiers, P.
(2013). Methylphenidate reduces functional connectivity of nucleus accumbens in brain
reward circuit. Psychopharmacology, 229(2), 219–226. https://doi.org/10.1007/s00213-0133105-x
Ramaekers, J. G., van Wel, J. H., Spronk, D., Franke, B., Kenis, G., Toennes, S. W., … Verkes,
R. J. (2016). Cannabis and cocaine decrease cognitive impulse control and functional
corticostriatal connectivity in drug users with low activity DBH genotypes. Brain Imaging
and Behavior, 10(4), 1254–1263. https://doi.org/10.1007/s11682-015-9488-z
Ritsner, M.S. (2010). Brain Protection in Schizophrenia, Mood and Cognitive Disorders.
Springer Science and Business Media.
Robinson, D. G., Woerner, M. G., Alvir, J. M., Geisler, S., Koreen, A., Sheitman, B., …
Lieberman, J. A. (1999). Predictors of treatment response from a first episode of
schizophrenia or schizoaffective disorder. The American Journal of Psychiatry, 156(4),
544–9. https://doi.org/10.1176/ajp.156.4.544
Robinson, D. G., Woerner, M. G., Alvir, J. M. J., Geisler, S., Koreen, A., Sheitman, B., …
Lieberman, A. (1999). Predictors of Treatment Response From a First Episode of
Schizophrenia or Schizoaffective Disorder. American Journal of Psychiatry J Psychiatry,

76

Impact of Cannabis on Biomarkers of AP Treatment
1564. Retrieved from http://ajp.psychiatryonline.org/doi/pdf/10.1176/ajp.156.4.544
Robinson, S. M., Sobell, L. C., Sobell, M. B., & Leo, G. I. (2014). Reliability of the Timeline
Followback for cocaine, cannabis, and cigarette use. Psychology of Addictive Behaviors,
28(1), 154–162. https://doi.org/10.1037/a0030992
Sarpal, D. K., Argyelan, M., Robinson, D. G., Szeszko, P. R., Karlsgodt, K. H., John, M., …
Malhotra, A. K. (2016). Baseline striatal functional connectivity as a predictor of response
to antipsychotic drug treatment. American Journal of Psychiatry, 173(1), 69–77.
https://doi.org/10.1176/appi.ajp.2015.14121571
Sarpal, D. K., Robinson, D. G., Fales, C., Lencz, T., Argyelan, M., Karlsgodt, K. H., …
Malhotra, A. K. (2017). Relationship between Duration of Untreated Psychosis and Intrinsic
Corticostriatal Connectivity in Patients with Early Phase Schizophrenia.
Neuropsychopharmacology. https://doi.org/10.1038/npp.2017.55
Sarpal, D. K., Robinson, D. G., Lencz, T., Argyelan, M., Ikuta, T., Karlsgodt, K., … Malhotra,
A. K. (2015). Antipsychotic treatment and functional connectivity of the striatum in firstepisode schizophrenia. JAMA Psychiatry, 72(1), 5–13.
https://doi.org/10.1001/jamapsychiatry.2014.1734
Sarter, M., & Bruno, J. P. (1999). Abnormal regulation of corticopetal cholinergic neurons and
impaired information processing in neuropsychiatric disorders. Trends in
neurosciences, 22(2), 67-74.
Schnell, T., Koethe, D., Daumann, J., & Gouzoulis-Mayfrank, E. (2009). The role of cannabis in
cognitive functioning of patients with schizophrenia. Psychopharmacology, 205(1), 45-52.
Schoeler, T., Kambeitz, J., Behlke, I., Murray, R., & Bhattacharyya, S. (2016a). The effects of
cannabis on memory function in users with and without a psychotic disorder: findings from

77

Impact of Cannabis on Biomarkers of AP Treatment
a combined meta-analysis. Psychological medicine, 46(1), 177-188.
Schoeler, T., Monk, A., Sami, M. B., Klamerus, E., Foglia, E., Brown, R., … Bhattacharyya, S.
(2016b). Continued versus discontinued cannabis use in patients with psychosis: a
systematic review and meta-analysis. The Lancet Psychiatry, 3(3), 215–225.
https://doi.org/10.1016/S2215-0366(15)00363-6
Schooler, N., Khan, A., Keefe, R., Robinson, D., & Kane, J. (2017). Cognitive Functioning in
First-Episode Psychosis:_Comparison of a 2-Year Coordinated Specialty Care Program to
Community Care. Schizophrenia Bulletin, 43(suppl_1), S24–S24.
https://doi.org/10.1093/schbul/sbx021.062
Schrantee, A., Ferguson, B., Stoffers, D., Booij, J., Rombouts, S., & Reneman, L. (2016). Effects
of dexamphetamine-induced dopamine release on resting-state network connectivity in
recreational amphetamine users and healthy controls. Brain Imaging and Behavior, 10(2),
548–558. https://doi.org/10.1007/s11682-015-9419-z
Seeman, P., & Lee, T. (1975). Antipsychotic drugs: direct correlation between clinical potency
and presynaptic action on dopamine neurons. Science, 188(4194), 1217-1219.
Seidman, L. J., & Mirsky, A. F. (2017). Evolving notions of schizophrenia as a developmental
neurocognitive disorder. Journal of the International Neuropsychological Society, 23(9-10),
881-892.
Selya, A. S., Rose, J. S., Dierker, L. C., Hedeker, D., & Mermelstein, R. J. (2012). A Practical
Guide to Calculating Cohen’s f(2), a Measure of Local Effect Size, from PROC MIXED.
Frontiers in Psychology, 3(111), 1–6. https://doi.org/10.3389/fpsyg.2012.00111
Sevy, S., Burdick, K. E., Visweswaraiah, H., Abdelmessih, S., Lukin, M., Yechiam, E., &
Bechara, A. (2007). Iowa gambling task in schizophrenia: a review and new data in patients

78

Impact of Cannabis on Biomarkers of AP Treatment
with schizophrenia and co-occurring cannabis use disorders. Schizophrenia research, 92(13), 74-84.
Sheffield, J. M., Karcher, N. R., & Barch, D. M. (2018). Cognitive Deficits in Psychotic
Disorders: A Lifespan Perspective. Neuropsychology review, 28(4), 509–533.
https://doi.org/10.1007/s11065-018-9388-2
Shukla, D. K., Chiappelli, J. J., Sampath, H., Kochunov, P., Hare, S. M., Wisner, K., ... & Hong,
L. E. (2018). Aberrant Frontostriatal Connectivity in Negative Symptoms of Schizophrenia.
Schizophrenia bulletin.
Simpson, E. H., Kellendonk, C., & Kandel, E. (2010). A possible role for the striatum in the
pathogenesis of the cognitive symptoms of schizophrenia. Neuron, 65(5), 585-596.
Smith, M. J., Cobia, D. J., Wang, L., Alpert, K. I., Cronenwett, W. J., Goldman, M. B., …
Csernansky, J. G. (2014). Cannabis-Related Working Memory Deficits and Associated
Subcortical Morphological Differences in Healthy Individuals and Schizophrenia Subjects.
Schizophrenia Bulletin, 40(2), 287–299. https://doi.org/10.1093/schbul/sbt176
Smith, S. M., Jenkinson, M., Woolrich, M. W., Beckmann, C. F., Behrens, T. E. J., JohansenBerg, H., … Matthews, P. M. (2004). Advances in functional and structural MR image
analysis and implementation as FSL. NeuroImage, 23, S208–S219.
https://doi.org/10.1016/j.neuroimage.2004.07.051
Sneider, J. T., Pope Jr, H. G., Silveri, M. M., Simpson, N. S., Gruber, S. A., & Yurgelun-Todd,
D. A. (2008). Differences in regional blood volume during a 28-day period of abstinence in
chronic cannabis smokers. European neuropsychopharmacology, 18(8), 612-619.
Sobell, L. C., & Sobell, M. B. (1992). Timeline Follow-Back. In Measuring Alcohol
Consumption (pp. 41–72). Totowa, NJ: Humana Press. https://doi.org/10.1007/978-1-4612-

79

Impact of Cannabis on Biomarkers of AP Treatment
0357-5_3
Sorg, C., Manoliu, A., Neufang, S., Myers, N., Peters, H., Schwerthöffer, D., … Riedl, V.
(2013). Increased Intrinsic Brain Activity in the Striatum Reflects Symptom Dimensions in
Schizophrenia. Schizophrenia Bulletin, 39(2), 387–395.
https://doi.org/10.1093/schbul/sbr184
Stasiewicz, P. R., Vincent, P. C., Bradizza, C. M., Connors, G. J., Maisto, S. A., & Mercer, N. D.
(2008). Factors affecting agreement between severely mentally ill alcohol abusers’ and
collaterals’ reports of alcohol and other substance abuse. Psychology of Addictive
Behaviors : Journal of the Society of Psychologists in Addictive Behaviors, 22(1), 78–87.
https://doi.org/10.1037/0893-164X.22.1.78
Stephan, K. E., Baldeweg, T., & Friston, K. J. (2006). Synaptic plasticity and dysconnection in
schizophrenia. Biological psychiatry, 59(10), 929-939.
Stokes, P. R. A., Mehta, M. A., Curran, H. V., Breen, G., & Grasby, P. M. (2009). Can
recreational doses of THC produce significant dopamine release in the human striatum?
NeuroImage, 48(1), 186–190. https://doi.org/10.1016/j.neuroimage.2009.06.029
Swendsen, J., Ben-Zeev, D., & Granholm, E. (2011). Real-Time Electronic Ambulatory
Monitoring of Substance Use and Symptom Expression in Schizophrenia. American
Journal of Psychiatry, 168(2), 202–209. https://doi.org/10.1176/appi.ajp.2010.10030463
Szeszko, P. R., Narr, K. L., Phillips, O. R., McCormack, J., Sevy, S., Gunduz-Bruce, H., …
Robinson, D. G. (2012). Magnetic Resonance Imaging Predictors of Treatment Response in
First-Episode Schizophrenia. Schizophrenia Bulletin, 38(3), 569–578.
https://doi.org/10.1093/schbul/sbq126
Tanda, G., Pontieri, F. E., & Di Chiara, G. (1997). Cannabinoid and heroin activation of

80

Impact of Cannabis on Biomarkers of AP Treatment
mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science,
276(5321), 2048–50. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9197269
Tomasi, D., & Volkow, N. D. (2013). Striatocortical pathway dysfunction in addiction and
obesity: differences and similarities. Critical Reviews in Biochemistry and Molecular
Biology. https://doi.org/10.3109/10409238.2012.735642
Torgalsbøen, A. K., Mohn, C., & Rund, B. R. (2014). Neurocognitive predictors of remission of
symptoms and social and role functioning in the early course of first-episode schizophrenia.
Psychiatry research, 216(1), 1-5.
Toulopoulou, T., Goldberg, T. E., Mesa, I. R., Picchioni, M., Rijsdijk, F., Stahl, D., ... &
Weinberger, D. R. (2010). Impaired intellect and memory: a missing link between genetic
risk and schizophrenia?. Archives of general psychiatry, 67(9), 905-913.
Trampush, J. W., Lencz, T., DeRosse, P., John, M., Gallego, J. A., Petrides, G., ... & Tohen, M.
(2015). Relationship of cognition to clinical response in first-episode schizophrenia
spectrum disorders. Schizophrenia bulletin, 41(6), 1237-1247.
Trifilieff, P., & Martinez, D. (2014). Imaging addiction: D2 receptors and dopamine signaling in
the striatum as biomarkers for impulsivity. Neuropharmacology, 76 Pt B(0 0), 498–509.
https://doi.org/10.1016/j.neuropharm.2013.06.031
Tu, P.-C., Lee, Y.-C., Chen, Y.-S., Li, C.-T., & Su, T.-P. (2013). Schizophrenia and the brain’s
control network: Aberrant within- and between-network connectivity of the frontoparietal
network in schizophrenia. Schizophrenia Research, 147(2–3), 339–347.
https://doi.org/10.1016/j.schres.2013.04.011
Vadhan, N. P., Corcoran, C. M., Bedi, G., Keilp, J. G., & Haney, M. (2017). Acute effects of
smoked marijuana in marijuana smokers at clinical high-risk for psychosis: A preliminary

81

Impact of Cannabis on Biomarkers of AP Treatment
study. Psychiatry research, 257, 372-374.
van de Giessen, E., Weinstein, J. J., Cassidy, C. M., Haney, M., Dong, Z., Ghazzaoui, R., …
Abi-Dargham, A. (2017). Deficits in striatal dopamine release in cannabis dependence.
Molecular Psychiatry, 22(1), 68–75. https://doi.org/10.1038/mp.2016.21
Van Rossum JM (1966). The significance of dopamine-receptor blockade for the mechanism of
action of neuroleptic drugs. Archives Internationales de Pharmacodynamie et de Therapie,
160 92–94.
Vandrey, R., Raber, J. C., Raber, M. E., Douglass, B., Miller, C., & Bonn-Miller, M. O. (2015).
Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis
Products. JAMA, 313(24), 2491–2493.
W, G., & Bonato, R. (1976). CGI: Clinical Global Impressions. ECDEU Assessment Manual for
Psychopharmacology, Revised, 217–222.
Walter, H., Kammerer, H., Frasch, K., Spitzer, M., & Abler, B. (2009). Altered reward functions
in patients on atypical antipsychotic medication in line with the revised dopamine
hypothesis of schizophrenia. Psychopharmacology, 206(1), 121–132.
https://doi.org/10.1007/s00213-009-1586-4
Winton-Brown, T. T., Allen, P., Bhattacharrya, S., Borgwardt, S. J., Fusar-Poli, P., Crippa, J. A.,
... & Atakan, Z. (2011). Modulation of auditory and visual processing by delta-9tetrahydrocannabinol and cannabidiol: an FMRI study. Neuropsychopharmacology, 36(7),
1340-1348.
Wisdom, J. P., & Manuel, J. I. (2011). Prevalence of Substance Use in People With FirstEpisode Psychosis. Journal of Dual Diagnosis, 7(figure 6), 39–49.
https://doi.org/10.1080/15504263.2011.569876

82

Impact of Cannabis on Biomarkers of AP Treatment
Wisdom, J. P., Manuel, J. I., & Drake, R. E. (2011). Substance Use Disorder Among People
With First-Episode Psychosis: A Systematic Review of Course and Treatment. Psychiatric
Services, 62(9), 1007–1012. https://doi.org/10.1176/appi.ps.62.9.1007.Substance
Wise, R. A. (2009). Roles for nigrostriatal--not just mesocorticolimbic--dopamine in reward and
addiction. Trends in Neurosciences, 32(10), 517–24.
https://doi.org/10.1016/j.tins.2009.06.004
Wu, E. Q., Shi, L., Birnbaum, H., Hudson, T., & Kessler, R. (2006). Annual prevalence of
diagnosed schizophrenia in the USA: a claims data analysis approach. Psychological
medicine, 36(11), 1535-1540.
Yücel, M., Bora, E., Lubman, D. I., Solowij, N., Brewer, W. J., Cotton, S. M., ... & McGorry, P.
D. (2012). The impact of cannabis use on cognitive functioning in patients with
schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample.
Schizophrenia bulletin, 38(2), 316-330.
Zammit, S., Moore, T. H. M., Lingford-Hughes, A., Barnes, T. R. E., Jones, P. B., Burke, M., &
Lewis, G. (2008). Effects of cannabis use on outcomes of psychotic disorders: systematic
review. The British Journal of Psychiatry, 193(5), 357–363.
https://doi.org/10.1192/bjp.bp.107.046375
Zavitsanou, K., Ward, P. B., & Huang, X. F. (2002). Selective alterations in ionotropic glutamate
receptors in the anterior cingulate cortex in
schizophrenia. Neuropsychopharmacology, 27(5), 826-833.
Zhou, F. C., Xiang, Y. T., Wang, C. Y., Dickerson, F., Kreyenbuhl, J., Ungvari, G. S., ... & Man,
D. (2014). Predictive Value of Prospective Memory for Remission in First‐Episode
Schizophrenia. Perspectives in psychiatric care, 50(2), 102-110.

83

Impact of Cannabis on Biomarkers of AP Treatment
Zink, C. F., Pagnoni, G., Martin, M. E., Dhamala, M., & Berns, G. S. (2003). Human Striatal
Response to Salient Nonrewarding Stimuli. The Journal of Neuroscience : The Official
Journal of the Society for Neuroscience, 23(22), 8092–8097. https://doi.org/02706474/03/238092-06.00/0

84

Impact of Cannabis on Biomarkers of AP Treatment
Table 1
A breakdown of study procedures is displayed in the table below:
Study Visit

Baseline

Week 6

Week 12

MRI Scan

X

Clinical Ratings

X

Neuropsychological Battery

X

Timeline Follow Back
Method

X

X

X

Urine Toxicology Screen

X

X

X

X
X

X
X
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Table 2. Differences in demographics, substance use patterns and neuropsychological
functioning between cannabis non-users and users included in Aim 1.

Cannabis Non-Users
(n=33)
Male Gender
Race
Caucasian
African American
Asian
Other

33.3%

Cannabis Users
(n=43)
65.1%

Statistics
df

χ²

p

1

7.55

.006

3

8.78

.03

39.4
30.3
24.2
6.1

25.6
48.8
7
18.6

Nicotine User

18.2

51.2

1

8.73

.003

Alcohol User

42.4

79.1

1

10.78

.001

0

14

1

5.00

.03

Used Other Substances

Other Substance User

Mean Age (SD)
Education
Total Brief Psychiatric
Rating Scale
BPRS Subscales
Thinking Disturbance
Withdrawal (Negative)
Hostility/Suspicion
Affective
Activation
Other Substance Use
Striatal Connectivity Index

26.56 (6.21)
13.09 (2.08)
45.36 (7.25)

22.56 (4.47)
13.32 (1.97)
45.84 (7.23)

55.75
69
74

3.13
-.47
-.28

.003
.64
.78

11.61 (2.35)
3.21 (1.45)
8.36 (1.88)
9.58 (3.67)
4.33 (2.31)

11.42 (2.28)
3.02 (1.82)
9.91 (2.10)
9.16 (3.79)
4.30 (1.91)

74
74
74
74
74

.35
.49
-3.32
.47
.06

.73
.63
.001
.64
.95

-3.94 (2.10)

-4.11 (2.15)

55

.31

.76

Marijuana Use in Last 6
Weeks
# of Days Nicotine Used in
Last 6 Weeks
Average Nicotine Use/Day

0 (0)

21.47 (14.49)

42

-9.72

.00

4.12 (11.72)

10 (15.84)

73.92

-1.86

.07

.87 (2.56)

3.69 (8.14)

50.93

-2.12

.04
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# of Days Alcohol Used in
Last 6 Weeks
Average Alcoholic
Drinks/Day
Neuropsychological
Performance
Speed of Processing
Attention & Vigilance
Working Memory
Verbal Learning
Visual Learning
Reasoning and ProblemSolving
Social Cognition
Overall Cognition

3.03 (8.41)

5.33 (8.68)

74

-1.16

.25

.97 (1.36)

3.16 (3.70)

55.84

-3.60

.001

34.48 (13.87)
29.09 (10.39)
37.36 (11.35)
40.21 (9.34)
36.79 (16.36)
44.27 (10.98)

34.83 (10.35)
29.60 (9.42)
36.21 (10.15)
37.86 (7.72)
38.14 (11.07)
41.21 (11.16)

57.83
71
74
74
53.43
74

-.12
-.22
.47
1.20
-.41
1.19

.91
.83
.64
.23
.90
.24

42.33 (13.46)
30.67 (14.74)

46.05 (11.24)
30.53 (9.99)

62.45
54.43

-1.26
.05

.21
.96
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Table 3. Differences in demographics, substance use patterns and neuropsychological
functioning between cannabis non-users and heavy cannabis users included in Aim 1.

Cannabis Non-Users
(n=33)

Mean Age (SD)
Education
Total Brief Psychiatric Rating
Scale (BPRS)
BPRS Subscales
Thinking Disturbance
Withdrawal (Negative)
Hostility/Suspicion
Affective
Activation
Other Substance Use

Heavy Cannabis
Users (n=16)

Statistics
df

t

p

26.56 (6.21)
13.09 (2.08)
45.36 (7.25)

23.80 (4.86)
13.63 (2.28)
45.31 (6.04)

47
47
47

1.56
-.82
.02

.13
.42
.98

11.61 (2.34)
3.21 (1.45)
8.36 (1.88)
9.58 (3.67)
4.33 (2.31)

11.63 (2.13)
2.5 (1.51)
10 (2.20)
9.63 (3.26)
3.81 (1.22)

47
47
47
47
47

-0.3
1.59
-2.70
-0.47
.84

.98
.19
.01
.96
.40

Marijuana Use in Last 6 Weeks
0 (0)
# of Days Nicotine Used in Last 6 4.12 (11.72)
Weeks
Average Nicotine Use/Day
.87 (2.56)
# of Days Alcohol Used in
3.03 (8.41)
Last 6 Weeks
Average Alcoholic
.97 (1.36)
Drinks/Day
Neuropsychological
Performance
Speed of Processing
34.48 (13.87)
Attention & Vigilance
29.09 (10.39)
Working Memory
37.36 (11.35)
Verbal Learning
40.21 (9.34)
Visual Learning
36.79 (16.36)
Reasoning and Problem44.27 (10.98)
Solving
Social Cognition
42.33 (13.46)
Overall Cognition
30.67 (14.74)

37 (4.35)
14.50 (18.36)

42
73.92

-9.72
-1.86

.00
.07

6.98 (11.64)
8.25 (12.05)

50.93
74

-2.12
-1.16

.04
.25

4.25 (4.78)

55.84

-3.60

.001

35.81 (14.17)
27.47 (11.46)
36.69 (14.05)
38.75 (8.50)
38.81 (12.802)
40.94 (12.85)

57.83
71
74
74
53.43
74

-.12
-.22
.47
1.20
-.41
1.19

.91
.83
.64
.23
.90
.24

47.87 (11.78)
31.87 (13.46)

62.45
54.43

-1.26
.05

.21
.96
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Table 4. Differences in demographics, substance use patterns, and neuropsychological
performance between patients who responded to antipsychotic treatment after 12 weeks and
patients who did not respond to treatment.

Male Gender
Race
Caucasian
African American
Asian
Other
Used Other Substances

Non-Responders
(n=12)
Percentage (%)

Responders (n=27)

Statistics

Percentage (%)

df

χ²

p

25.0

63.0

1

4.79

.03

3

4.44

.22

41.7
33.3
8.3
16.7

22.2
51.9
22.2
3.7

Cannabis User

25

59.3

1

3.90

.05

Nicotine User

25

33.3

1

.27

.60

Alcohol User

50

55.6

1

.10

.75

Other Substance User

8.3

7.4

1
df

.01
t

.92
p

Mean Age (SD)
Education
Striatal Connectivity Index

25.51 (8.17)
12.08 (2.07)
-4.45 (1.97)

23.22 (4.69)
13.63 (1.86)
-3.48 (2.30)

14.32
37
44

.91
-2.31
-1.51

.38
.03
.14

Marijuana Use in Last 18
Weeks
# of Days Nicotine Used
in Last 18 Weeks
# of Days Other Drugs
Used
# of Days Alcohol Used in
Last 18 Weeks
Baseline
Neuropsychological
Performance
Speed of Processing
Attention & Vigilance

13.67 (31.35)

16.26 (23.72)

37

-.29

.78

1.42 (3.03)

23.37 (42.65)

26.59

-2.67

.01

16.25 (31.34)

9.63 (24.37)

37

.72

.48

4.83 (8.02)

5.15 (7.6)

37

-.12

.91

38.17 (10.89)
30.67 (8.84)

36.30 (12.65)
28.22 (9.60)

37
37

.44
.75

.67
.46
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Working Memory
Verbal Learning
Visual Learning
Reasoning and ProblemSolving
Social Cognition
Overall Cognition

39.92 (13.36)
39.33 (9.07)
35.42 (16.48)
45.25 (12.05)

36.81 (9.16)
39.00 (9.10)
40.00 (12.28)
41.48 (9.86)

37
37
37
37

.85
.11
-.97
1.03

.40
.92
.34
.31

41.75 (13.65)
32.58 (12.34)

44.11 (10.57)
30.56 (12.28)

37
37

-.58
.48

.56
.64
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Table 5. Differences in demographics, substance use patterns and striatal connectivity index
between cannabis non-users and users included in Aim 2.

Male Gender
Race
Caucasian
African American
Asian

Cannabis Non-Users
(n=26)
Percentage (%)

Cannabis Users
(n=32)
Percentage (%)

Statistics
df

χ²

p

30.8

59.4

1

4.72

.03

3

8.71

.03

38.5
30.8
23.1

25
50
3.1

Other
Used Other Substances

7.7

21.9

Nicotine User

19.2

46.9

1

4.85

.03

Alcohol User

42.3

75

1

6.41

.01

0

12.5

1
df

3.49
t

.06
p

Other Substance User

Mean Age (SD)
Education
Total Brief Psychiatric
Rating Scale
Striatal Connectivity Index
BPRS Subscales
Thinking Disturbance
Withdrawal (Negative)
Hostility/Suspicion
Affective
Activation
Other Substance Use
BPRS Subscales
Marijuana Use in Last 6
Weeks
# of Days Nicotine Used
in Last 6 Weeks
Average Nicotine Use/Day
# of Days Alcohol Used in
Last 6 Weeks

26.25 (6.48)
13.24 (2.20)
45.42 (7.62)

22.54 (4.37)
13.47 (2.06)
45.06 (7.46)

42.24
53
56

2.49
-.39
.18

.02
.70
.86

-3.80 (2.16)

-4.11 (2.15)

56

.54

.59

11.31 (2.28)
3.35 (1.55)
8.12 (1.84)
10.15 (3.51)
4.00 (1.72)

11.41 (2.26)
3.06 (1.85)
10.13 (1.95)
8.59 (3.77)
4.13 (1.81)

56
56
56
56
56

-.17
.62
-4.01
1.62
-.27

.87
.56
.00
.11
.79

0 (0)

19.78 (14.63)

31

-7.65

.00

3.46 (10.06)

7.66 (13.76)

56

-1.30

.20

.72 (2.20)
3.5 (9.42)

2.16 (4.89)
3.41 (4.70)

56
56

-1.40
.05

.17
.96
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Average Alcoholic
Drinks/Day

.96 (1.37)

2.66 (2.51)

92

56

-3.09

.003
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Table 6. Differences in demographics, substance use patterns and striatal connectivity index
between cannabis non-users and heavy users included in Aim 2.
Cannabis NonUsers (n=33)

Heavy Cannabis
Users (n=16)

Statistics
df

t

p

Mean Age (SD)
Education
Striatal Connectivity Index
Total Brief Psychiatric Rating
Scale (BPRS)
BPRS Subscales
Thinking Disturbance
Withdrawal (Negative)
Hostility/Suspicion
Affective
Activation
Other Substance Use

26.24 (6.48)
13.24 (2.20)
-3.78 (2.15)
45.42 (7.62)

23.62 (4.60)
13.82 (2.48)
-4.19 (3.28)
42.82 (4.62)

35
34
35
35

1.22
-.70
.46
1.05

.23
.49
.65
.30

11.31 (2.28(
3.35 (1.55)
8.12 (1.84)
10.15 (3.51)
4 (1.72)

11.36 (1.91)
2.00 (0)
10.09 (2.43)
8.45 (2.84)
3.55 (.93)

35
25
35
35
35

-.07
4.44
-2.71
1.42
.82

.94
.00
.01
.17
.42

Marijuana Use in Last 6 Weeks
# of Days Nicotine Used in Last 6
Weeks
Average Nicotine Use/Day
# of Days Alcohol Used in Last 6
Weeks
Average Alcoholic Drinks/Day

0 (0)
3.46 (10.06)

36.45 (4.32)
10.64 (16.56)

10
13.24

-27.98
-1.34

.00
.20

.72 (2.20)
3.50 (9.42)

4.36 (7.80)
4.91 (5.87)

10.68
35

-1.53
-.46

.16
.65

.96 (1.37)

3.18 (2.40)

12.85

-2.88

.01
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Table 7. Differences in demographics, substance use patterns, and striatal connectivity index
between patients who responded to antipsychotic treatment after 12 weeks and patients who did
not respond to treatment.

Male Gender
Race
Caucasian
African American
Asian
Other
Used Other Substances

Non-Responders
(n=10)
Percentage (%)

Responders (n=22)

Statistics

Percentage (%)

df

χ²

p

20.0

59.1

1

4.22

.04

3

3.66

.30

40.0
30.0
10.0
20.0

22.7
54.5
18.2
4.5

Cannabis User

30

59.1

1

2.33

.13

Nicotine User

30

27.3

1

.03

.87

Alcohol User

50

50

1

.00

1.00

Other Substance User

10

4.5

1
df

.35
t

.56
p

Mean Age (SD)
Education
Total Brief Psychiatric
Rating Scale S
Striatal Connectivity Index

25.66 (8.50)
12.20 (2.25)
45 (6.01)

23.26 (4.52)
13.64 (1.94)
44.45 (6.68)

11.38
30
30

.84
-1.85
.22

.42
.08
.83

-5.13 (1.72)

-3.01 (2.20)

29

-2.67

.01

Marijuana Use in 6 weeks
Prior to Baseline Scan
Marijuana Use in Last 18
Weeks
# of Days Nicotine Used
in Last 18 Weeks
# of Days Other Drugs
Used
# of Days Alcohol Used in
Last 18 Weeks

6.20 (12.16)

9.86 (14.28)

30

-.70

.49

16 (34.11)

17.64 (25.06)

30

-.15

.88

1.70 (3.27)

20.41 (39.83)

21.62

-2.19

.04

19.50 (33.62)

7.55 (20.61)

12.19

1.04

.32

5.30 (8.71)

5.00 (7.57)

30

.10

.92

94
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Figure 1. Location of Striatal Functional Connections included in the Striatal Connectivity
Index: This figure depicts the functional connections with the striatum that had a predictive value
and were included in the computation of the striatal connectivity index as a biomarker.

95

Impact of Cannabis on Biomarkers of AP Treatment

Responders

Non-Responders

Figure 2. Baseline Striatal Connectivity Index Demonstrated to Distinguish Responders from
Non-Responders: Patients who responded to antipsychotic medication showed a lower striatal
connectivity index at baseline compared to those who did not respond to medication.
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Figure 3. Functional Connectivity Changes Pre-and-Post 12 weeks of Antipsychotic Treatment:
An improvement in psychotic symptomology was previously found to be related to the extent of
functional connectivity change between the striatum and other important regions of the brain.
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Figure 4. Preliminary Analysis to Examine the Impact of Cannabis Use Disorder (CUD) on the
Established Relationship Between Baseline Striatal Connectivity Index (SCI) and Antipsychotic
Treatment (AP) Response: This graph shows the different results between the relationship of the
SCI and AP response when a sample of patients with schizophrenia spectrum disorders (SSD) (N
= 41) was divided into patients with (CUD+) and without a history of CUD (CUD-). Logistic
regression analysis revealed the magnitude of the relationship between SCI and treatment
response was very large for those without a CUD diagnosis at baseline (r2 = 0.86, p < 0.0001, β =
-2.27) while for those with a CUD diagnosis history, the magnitude of the effect of SCI on
treatment response was much smaller (r2 = 0.20, p = 0.10, β = -0.23).

98

Impact of Cannabis on Biomarkers of AP Treatment

Figure 5. Scatterplot of the Differing Relationship between Striatal Connectivity Index and
Cannabis Use for Responders and Non-Responders: This graph shows that when the sample was
divided into patients who responded to antipsychotic drug (AP) treatment (Responders) and
those who did not (Non-Responders), the relationship between the striatal connectivity index
(SCI) and total cannabis use before and over the course of AP treatment differed for each group.
A post-hoc analysis divided the sample into responders and non-responders, and used a linear
regression to evaluate the impact of cannabis use on the SCI. Baseline cannabis use was entered
as the predictor variable and the SCI was entered as the outcome variable. The results
demonstrated that for non-responders, there was a significant negative relationship between
baseline cannabis use and the SCI (p = .005, β = -.802) whereas there was no significant
relationship for responders (p = .28, β = .25). This suggests that cannabis use may differentially
affect the SCI for responders and non-responders.
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